Tyrosine Kinase Inhibition in Experimental Kidney Transplantation by Rintala, Jukka
 
Faculty of Medicine 
Doctoral Programme in Biomedicine 
University of Helsinki 
Finland 
 




Jukka Rintala, MD 
Kidney Transplant Research Group, Transplantation Laboratory, 
University of Helsinki/ 
Transplantation and Liver Surgery Unit, 




To be publicly discussed with the permission of the Faculty of Medicine,  
University of Helsinki, 
In Lecture Room 1, at Haartman Institute, Helsinki, 





Docent Johanna Savikko, MD, PhD 
Kidney Transplant Research Group, Transplantation Laboratory, University of 
Helsinki/ 
Transplantation and Liver Surgery Unit, 





Professor Ilkka Pörsti, MD, PhD 
Department of Internal Medicine,  






Docent Mikko Pakarinen MD, PhD  
Section of Pediatric Surgery, Children's Hospital,  
Helsinki University Central Hospital, 





Associate Professor Josep M. Cruzado, MD, PhD 
Department of Nephrology, Hospital Universitari de Bellvitge, 













CONTENTS          3 
 
ORIGINAL PUBLICATIONS       7 
 
ABBREVIATIONS         8 
 
INTRODUCTION         10 
 
REVIEW OF LITERATURE        13 
1. Clinical kidney transplantation       13 
2. Transplant immunology       14 
2.1 Donor type       15 
2.2 Ischemia reperfusion injury     15 
2.3 Innate immunity       16 
2.4 Adaptive immunity      16 
3. Renal allograft rejection       17 
3.1. Allorecognition       17 
3.2 Antigen presentation      18 
3.3 Dendritic cells       18 
3.4 Monocyte-macrophages      19 
3.5 NK cells        19 
3.6 Activation of adaptive immunity     20 
   3.6.1 T-cell activation      20 
   3.6.2 B-cell activation      21 
  3.7 Rejection classification and scoring    21 
 4 
3.7.1 Banff classification     21 
3.7.2 CADI score      22 
4. Immunosuppressive medication      23 
4.1 Corticosteroids       23 
4.2 Calcineurin inhibitors      23 
4.3 Antiproliferative drugs      24 
4.4 Antibodies        25 
5. Cytokines and growth factors      26 
5.1 Platelet-derived growth factor (PDGF)    26 
5.2 Vascular endothelial growth factor (VEGF)    27 
5.3 transforming growth factor beta (TGF-β)    28 
5.4 epidermal growth factor (EGF)     29 
5.5 Growth factor interactions      30 
5.6 Growth factors in end-stage renal disease    32 
5.7 Growth factors in transplantation     33 
6. Tyrosine kinase inhibition       36 
6.1 Tyrosine kinases as growth factor receptors    36 
6.2 Tyrosine kinase inhibitors      36 
6.2.1 FK778        37 
6.2.2 Imatinib        38 
6.2.3 Erlotinib        39 
6.2.4 Sunitinib       40 
 
AIMS OF THE STUDY        41 
METHODS          42 
 5 
1. Experimental strategy        42 
2. Experimental animals        43 
3. Rat aorta denudation model       43 
4. Experimental kidney transplantation in rats     44 
5. Drug regimens        44 
6. Histology         45 
7. Immunohistochemistry       46 
8. In vitro studies        47 
9. Statistical analysis        48 
 
RESULTS          50 
1. Clinical course         50 
2. The effect of erlotinib and sunitinib on neointimal formation   50 
3. The effect of  sunitinib on SMC proliferation and migration   50 
4. Acute rejection         51 
5. Graft function and serum creatinine levels      51 
6. Chronic rejection        52 
7. Post-transplant growth factor expression     53 
7.1 PDGF         53 
7.2 TGF-β         54 
7.3 VEGF         54 





DISCUSSION          56 
 1. Growth factor expression in syngenic grafts     56 
 2. FK778 ameliorates acute and chronic rejection     56 
 3.  Short-term imatinib treatment prevents chronic rejection   57 
4. EGF inhibition with erlotinib prevents chronic rejection and maintains  
   renal function         58
 5. Sunitinib prevents chronic allograft injury and preserves kidney  
    function          59 
6. Tyrosine kinase inhibition in experimental kidney transplantation  60 
 
CONCLUSIONS         62 
LIMITATIONS OF THE STUDY       63 
SUMMARY          65 
YHTEENVETO (FINNISH SUMMARY)      67 
ACKNOWLEGDEMENTS        70 





This thesis is based on the following original publications referred to in the text by 
their Roman numerals. 
 
I Rintala JM, Savikko J, Rintala SE, von Willebrand E. FK778 ameliorates 
post-transplant expression of fibrogenic growth factors and development of  
chronic rejection changes in rat kidney allografts. 2008. Nephrol Dial 
Transplant. 23(11):3446-55. 
 
II Savikko J, Rintala JM, Rintala SE, Koskinen PK, von Willebrand E. Early 
short-term imatinib treatment is sufficient to prevent the development of  
chronic allograft nephropathy. 2011. Nephrol Dial Transplant. 26(9):3026-32. 
 
III Rintala JM, Savikko J, Palin N, Rintala SE, Koskinen PK, von Willebrand E. 
Epidermal growth factor inhibition, a novel pathway to prevent chronic 
allograft injury. 2014. Transplantation. 27;98(8):821-7.  
 
IV  Rintala JM, Savikko J, Palin N, Rintala SE, Koskinen PK, von Willebrand E. 
Oral Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor 
Inhibitor Sunitinib Prevents Chronic Allograft Injury in Experimental Kidney 




APC  antigen-presenting cell 
AZA  Azathioprine  
CAD  chronic allograft dysfunction  
CADI  Chronic Allograft Damage Index 
CAI  Chronic allograft injury 
CAN  chronic allograft nephropathy  
CMV  cytomegalovirus 
CNI  calcineurin inhibitor 
CsA  cyclosporine A 
CTL  cytotoxic T lymphocyte 
DA  Dark Agouti  
DAMP  damage-associated molecular pattern 
EGF  epidermal growth factor 
EGFR  epidermal growth factor receptor 
ESRD  end-stage renal disease 
bFGF  Basic fibroblast growth factor 
GIST  gastro-intestinal stromal tumor 
HLA  human leukocyte antigen 
IFN-γ  interferon-gamma  
IL-2  interleukin 2 
IL-2R  interleukin 2 receptor 
IMPDH inosine 5-monophosphate dehydrogenase  
iNOS  inducible nitric oxide synthase 
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MCP-1 monocyte chemoattractant protein-1 
MHC  major histocompatibility complex 
MMF  mycophenolate mofetil 
NK cell natural killer cell 
PAMP   pathogen-associated molecular patterns  
PDGF  platelet-derived growth factor 
PDGFR platelet-derived growth factor receptor 
ROS  reactive oxygen species  
RT  room temperature 
RTK  receptor tyrosine kinase 
SMC  smooth muscle cell 
SRL  sirolimus 
Tac  tacrolimus 
TCR  T-cell receptor 
TGF-β  transforming growth factor beta 
Th-cell  helper T-cell 
TNF-α  tumor necrosis factor alpha 
VEGF  vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 








The development of modern surgery made experimental kidney transplantation 
possible at the beginning of the 20th century (Brown et al.  2010). In this early era, 
transplanted kidneys were rapidly lost due to non-surgical reasons that were 
impossible to investigate at the time. Increasing immunological knowledge led to the 
first successful human kidney transplant between identical twins in 1954 (Murray et 
al.  1958).  
Initially, acute rejection was a major clinical problem, causing early graft losses, 
because the immunosuppressive drug regimen was narrow and ineffective (Calne 
1968). Immunosuppressive treatment was revolutionized in the late 1970s when 
cyclosporine was introduced to treat acute rejection (Calne et al. 1978). Cyclosporine 
(CsA) treatment greatly improved transplantation results and made kidney 
transplantation a "gold standard" in the treatment of end-stage renal disease (ESRD). 
Cyclosporine was later followed by its competitor tacrolimus (Tac) (Kino et al. 1987), 
as well as other immunosuppressants, such as sirolimus (SRL) (Sacks 1999) and 
mycophenolate mofetil (MMF) (Platz et al. 1991). Combination therapies were 
developed to reduce the side effects of individual drugs and increase the 
immunosuppressive efficacy. These improvements further decreased the prevalence 
of acute rejection. However, long-term results failed to demonstrate significant 
progress in the prevalence of chronic rejection, and annual graft failure after 1 year 
has remained at 4% (Nankivell and Kuypers 2011). 
Chronic rejection is a multifactorial process driven by both immunological and non-
immunological factors, leading to organ failure (Nankivell and Kuypers 2011). ESRD 
alters the immunological response and may affect subsequent reactions to renal 
allografts (Anders et al.  2013). The transplantation process leads to both warm and 
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cold ischemia of the kidney graft and ischemia reperfusion injury after the graft is 
attached to the recipient’s circulation. These events may affect activation of the 
recipient’s immune system.  
The immune system recognizes foreign tissue via multiple pathways. Innate immunity 
is the first-line, pattern-recognizing, defense system that reacts to foreign or injured 
tissue; it is activated after solid organ transplantation (Cucchiari et al.  2016). 
Adaptive immunity is a more sophisticated and pathogen-specific immunogenic 
process that leads to an alloimmune response targeting the transplanted kidney graft 
(Nankivell and Kuypers 2011). The alloimmune response causes acute rejection, 
which destroys the graft unless treated with immunosuppressive drugs. Although 
acute rejection may be treated successfully, it is a major reason for subsequent 
chronic rejection. Retrospective analysis has detected other risk factors for the 
development of chronic rejection, but detailed factors are still unknown. No treatment 
is currently available for chronic rejection. 
Growth factors are ubiquitous peptides that mediate cell signaling and cellular 
processes in physiological and pathological environments. Many growth factors also 
participate in repair processes, such as wound healing (Bodnar 2015). Growth factors 
mediate their effects through specific receptors on the cell surface. Many of these 
receptors belong to the tyrosine kinase family, named for their induction of the intra-
cellular phosphate binding of signaling molecules (Liu and Zhuang 2016). Growth 
factor expression is increased during both acute and chronic rejection (Savikko et al.  
2001b) and participates in the interplay between innate and adaptive immunity (Kwan 
et al.  2014).  
Pathological overexpression of growth factors has been shown to be a common 
feature in the development of various types of cancer (Odenthal et al. 2016). Interest 
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in the discovery of drugs that inhibit the effect of growth factors led to the 
development of imatinib, the first oral tyrosine kinase inhibitor, which inhibits 
platelet-derived growth factor (PDGF) signaling (Deininger et al. 1997). The 
discovery revolutionized the treatment of chronic myeloid leukemia (Druker et al. 
2001). Other tyrosine kinase inhibitors have also been introduced for various cancers. 
In transplantation studies, growth factors such as PDGF (Weinman et al. 2002), 
vascular endothelial growth factor (VEGF) (Jimenez-Sousa et al. 2012), epidermal 
growth factor (EGF) (Nakopoulou et al. 1994), and transforming growth factor beta 
(TGF-β) (Jimenez-Sousa et al. 2012) appear to be active in the rejection process, but 
their exact roles remain unknown. Standard immunosuppressive treatment fails to 
prevent the post-transplant growth factor induction (Bennett et al. 2016; McMorrow 
et al. 2005) that may be an important factor in the development of subsequent chronic 
rejection. 
The aim of this study was to investigate the effect of four different growth factor 
response-inhibiting drugs on the development of chronic rejection and graft function 








REVIEW OF THE LITERATURE 
 
1. CLINICAL KIDNEY TRANSPLANTATION 
Despite the first experimental kidney transplantation being done in the beginning of 
the previous century, the first successful human kidney transplantation was not until 
1954 (Murray et al. 1958). The procedure was performed between identical twins to 
avoid rejection. Since that time, kidney transplantation has been an option for treating 
ESRD. However, acute rejection was a major obstacle in the survival of renal grafts 
until the introduction of cyclosporine in the 1970s. Cyclosporine enabled dramatically 
better results and transformed kidney transplantation into the treatment of choice for 
ESRD patients (Calne et al. 1978). The most common reasons for ESRD and 
subsequent kidney transplantation are diabetic nephropathy, hypertension, chronic 
glomerulonephritis and cystic renal disease (Matas et al. 2015). 
A shortage of kidney grafts limits the number of kidney transplantations, and 200-250 
such procedures are performed in Finland annually. The outcomes of kidney 
transplantation are superior to those of dialysis treatment with regard to the mortality 
rate and quality of life (Czyzewski et al. 2014; van Walraven et al.  2010). In addition, 
kidney transplantation is highly cost-effective (Kalo et al.  2001, Ortiz et al. 2014). 
The surgical results of kidney transplantation are good, though ESRD with prolonged 
uremia and vascular calcification often causes sclerotic arteries, which may 
complicate the creation of vascular anastomoses. Modern immunosuppressive 
medication has increased the successful treatment of acute rejection. With modern 
combination therapies biopsy proven acute rejection rate is 10-20% during the first 3 
years after transplantation (Hanaway et al. 2011; Matas et al. 2015). However, acute 
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rejection remains the main reason for early graft loss within the first year after 
transplantation (El-Zoghby et al. 2009). 
The development of modern immunosuppressive regimens has decreased graft loss 
due to acute rejection. However, the impact on long-term graft survival has been 
marginal (Matas et al. 2013; Nankivell and Kuypers 2011). Many different 
pathological causes contribute to late allograft loss (El-Zoghby et al. 2009), and the 
most prevalent cause of death among renal transplant patients is death due to 
cardiovascular diseases in the presence of a still functioning graft (Morath et al. 
2007). However, immunologically driven chronic rejection remains a major reason 
for late allograft loss (El-Zoghby et al. 2009). No treatment is currently available for 
chronic rejection. Optimizing standard immunosuppression or changing to another 
regimen has been suggested as treatment, but the evidence of efficacy in chronic 
rejection is scarce (Pascual et al. 2002; Soliman et al. 2014) though improvements in 
graft function have been reported (Plischke et al. 2015). Instead, the prevention of 
metabolic syndrome, obesity, hypercholesterolemia, and hypertension (Hricik 2011) 
and smoking cessation (Opelz and Dohler 2016) have been suggested as possible 
interventions against late graft loss.  
 
2. TRANSPLANT IMMUNOLOGY 
The recognition of foreign or injured material is crucial for maintaining body 
physiology and homeostasis and has been secured with multiple pathways during 
evolution. The immune system recognizes foreign material by both non-specific 
innate immunity (Cucchiari et al. 2016) and antigen-specific adaptive immunity 
(Nankivell and Kuypers 2011). These processes partly overlap. After recognition, 
various signaling cascades aim to activate both cellular and humoral responses against 
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foreign material. Patient-derived conditions, such as age, sex, and comorbidities, may 
modulate the recipient’s immune response. Clinically, these cascades lead to a 
rejection process.  
 
2.1 DONOR TYPE 
Most kidney allografts are derived from deceased donors. However, living kidney 
donation from a relative or non-relative is highly recommended to ease organ 
shortages and provide transplant options for ESRD patients. Living donor 
transplantations also result in lower graft failure rates than deceased donor grafts 
(Matas et al. 2013). Organs derived from deceased donors are typically retrieved from 
hospitals other than transplantation centers and have a longer cold ischemia time, 
which appears to activate innate immunity (Naesens et al. 2009). In addition, multi-
organ procurement of deceased donors increases circulating inflammatory biomarkers 
that may reduce organ quality (Auraen et al. 2013). Furthermore, brain death itself 
activates an inflammatory cascade that may activate an immunological response and 
affect post-transplant events (Pullerits et al. 2015).  
 
2.2 ISCHEMIA REPERFUSION INJURY 
The transplantation procedure includes cold ischemia during the surgery and 
transportation of the graft. Cold ischemia causes hypoxic cell injury and ultimately 
leads to cell death if continuing for too long. Prolonged ischemia also leads to the 
accumulation of reactive oxygen species (ROS) (Aksu et al. 2015), which may cause 
additional tissue injury after the graft is anastomosed to the recipient’s circulation 
(Cavaille-Coll et al. 2013). This process is called ischemia reperfusion injury. 
Ischemia reperfusion injury increases the post-transplant immunological response and 
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may be one factor in the initiation of the cascade from cell injury to increased 
inflammation, and even to acute and chronic rejection (Cavaille-Coll et al. 2013; Zhao 
et al. 2014). 
 
2.3 INNATE IMMUNITY 
Innate immunity is the first line of defense against pathogens and injured tissue. This 
process consists of natural killer (NK) cells, dendritic cells, monocyte-macrophages, 
neutrophils, and the complement system. Innate immunity is not allo-specific and 
lacks immunological memory. Instead, it is a pattern-recognizing response that reacts 
to any abnormal tissue residues encountered (Rosin and Okusa 2011). Therefore, it 
reacts to foreign tissue and injured tissue, inducing reparative cascades. Innate 
immunity is activated upon the recognition of pathogen-associated molecular patterns 
(PAMPs) or damage-associated molecular patterns (DAMPs). In renal transplantation, 
innate immunity may react against DAMPs that are released during ischemia 
reperfusion injury (Cucchiari et al. 2016).  
 
2.4 ADAPTIVE IMMUNITY 
Adaptive immunity is a more specific immunological response that points to foreign 
antigens that are recognized by the immune system. After foreign tissue is recognized 
by antigen-presenting cells (APCs), they activate adaptive immunity through specific 
T-cells for cellular adaptive immunity and B-cells for humoral adaptive immunity. 
Adaptive immunity has long-term memory responses that enable rapid immune 




3. RENAL ALLOGRAFT REJECTION 
Rejection is an immune response that induces and mediates injury in the allograft. 
Clinically, the rejection process is categorized as hyperacute, acute, or chronic. In 
addition to the rejection process, background pathology leading to the development of 
ESRD, such as diabetes or process behind glomerular disorder, may continue to affect 
the rejection process in a kidney graft.  
Hyperacute rejection begins almost immediately after re-circulation of the graft and 
requires previous exposure to alloantigen. Therefore, this type of rejection can be 
prevented with adequate antibody cross-matching. Thus, hyperacute rejection is rare 
(Nankivell and Alexander 2010). 
Acute rejection occurs in the early post-transplant period, most commonly in the first 
few months. Clinically, an increase in serum creatinine is considered a sign of acute 
rejection (KDIGO Clinical Practice Guideline 2009). Ultrasonography-assisted renal 
biopsies are taken when acute rejection is suspected, and episodes of acute rejection 
are treated with a short-term corticosteroid and by optimizing the immunosuppressive 
regimen (Baker et al. 2017). 
Chronic rejection is a slower fibrotic process that leads to organ failure. It can begin 
any time after transplantation. Histologically, it is characterized by interstitial fibrosis, 
chronic inflammation, allograft arteriosclerosis, and tubular and glomerular lesions 
(Hayry et al. 1993; Solez et al. 1993).  
 
3.1 ALLORECOGNITION 
A key step in activation of the immune system in solid organ transplantation is the 
recognition of foreign tissue or material. The immune system recognizes foreign 
material based on cell surface antigens that differ from self-antigens (Nankivell and 
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Alexander 2010). All cell surfaces are coated with major histocompatibility complex 
(MHC) molecules that present cell antigens on the cell surface. MHC molecules are 
heterodimers consisting of α- and β-chains and form two classes: MHC I and MHC 
II. Human MHC molecules are called human leukocyte antigens (HLAs) (Nankivell 
and Alexander 2010). MHC I molecules are present in almost all nucleus-containing 
cells and present internal cellular peptides. MHC II molecules are found on the 
surface of APCs, such as macrophages, dendritic cells, and B-lymphocytes and 
present extracellular peptides/proteins (Caron et al. 2015).  
 
3.2 ANTIGEN PRESENTATION 
APCs, such as monocyte-macrophages and dendritic cells, are part of innate immunity 
and important cells in the initiation of the immune response. After these cells 
encounter foreign tissue, they internalize the foreign antigens and then present them to 
B- and T-cells to activate allo-specific adaptive immunity.  
 
3.3 DENDRITIC CELLS 
Dendritic cells are part of innate immunity. They recognize DAMPs by their pattern 
recognition receptors, of which the Toll-like receptors are the most investigated 
(Zhuang and Lakkis 2015). Dendritic cells are the most potent APC´s with regard to 
activating T-cells (Steinman and Idoyaga 2010) and present in the kidney, where their 
numbers increase during inflammation (Nelson et al. 2012). Recent findings suggest 
that recipient dendritic cells activate T-cells in the transplanted kidney and sustain the 
alloimmune response, indicating their profound role in the development of rejection 





Monocytes are bone marrow-derived cells that enter organs after circulating for a few 
days in the bloodstream. In tissues, these monocytes differentiate into tissue 
macrophages and tissue dendritic cells (Rowshani and Vereyken 2012). Macrophages 
have no specific antigen receptors but are activated by cytokines, especially 
interferon-gamma (IFN-γ). Once activated, macrophages present two different states 
(Salehi and Reed 2015). M1 macrophages are mainly induced by IFN-γ and 
considered to be pro-inflammatory and cytotoxic, linked to the Th1 response. M2 
macrophages are inducible by interleukin (IL)-4, IL-13, and TGF-β and associated 
with the Th2 response and tissue modeling (Salehi and Reed 2015). In addition, M2s 
secrete growth factors, such as TGF-β and PDGF (Rowshani and Vereyken 2012). 
Macrophages also secrete toxic molecules, including superoxides and nitric oxide via 
inducible nitric oxide synthase (iNOS), which function as pro-inflammatory 
cytokines, and tumor necrosis factor alpha (TNF-α), which may mediate the rejection 
cascade (Kutukculer et al. 1995; Salehi and Reed 2015).  
 
3.5 NK CELLS 
NK cells are part of innate immunity; therefore, they lack allo-specificity and a 
memory response. NK cells may modulate the allo-specific immunoresponse and 
activate T-cells (Zecher et al. 2012) but may also induce tolerance on islet allografts 
(Beilke et al. 2005). In addition, NK cells have been shown to aggravate graft injury 
(Hirohashi et al. 2012). NK cells recognize foreign material via the activation of their 
clono-typic antigen receptor and require co-stimulation through the balance between 
the stimulatory and inhibitory signals of different cell surface receptors (Beilke and 
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Gill 2007). The role of NK cells in solid organ transplantation remains controversial. 
However, NK cells may have a role in mediating long-term graft injury 
experimentally (Zhang et al. 2015). 
 
3.6 ACTIVATION OF ADAPTIVE IMMUNITY 
 
3.6.1 T-CELL ACTIVATION 
T-cells mediate the adaptive immune response and are critical for the recognition of 
foreign tissue in a transplanted kidney graft in a process called allo-recognition. T-
cells can be activated via three different cascades. In direct allo-recognition, T-cells 
recognize intact foreign material. In indirect allo-recognition, they recognize foreign 
antigens processed and presented by APCs. This process requires that recipient APCs 
have encountered foreign material, which they process and then present in their MHC 
II molecules. Recently, it was proposed that T-cells recognize intact foreign 
antibodies presented by APCs in a semi-direct manner (Ali et al. 2013).  
After allo-recognition, T-cells are activated and further stimulate the immune 
response. However, full T-cell activation requires that T-cells bind MHC molecules 
via T-cell receptor (TCR), as well as co-stimulation. Otherwise, T-cells may become 
unresponsive in a process called anergy (Schietinger and Greenberg 2014). Various 
co-stimulatory routes have been described. The classical route includes B7 molecule 
on the APC surface and its binding to CD28 on the T-cell surface (Li et al. 2009). 
T-cells are divided into CD4+ helper T (Th) cells, which activate other cell types, and 
CD8+ cytotoxic T-cells, which induce the apoptosis of foreign cells. In particular, 
CD4+ T-cells are important in initiating allo-recognition. When Th-cells become fully 
activated, they cause T-cell proliferation, clonal expansion, and cytokine expression 
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in an autocrine pathway. During activation, Th-cells may become Th1-, Th2-, or 
Th17-lymphocytes depending on the surrounding cytokine environment (Wood and 
Goto 2012). These different Th-subclasses have different responses. Th1-cells 
produce IFN-γ and IL-2, leading to CD8-cytotoxicity and macrophage activation 
(Abdoli and Najafian 2014). Th2-cells secrete IL-4, IL-5, and IL-13, which lead to 
antibody production and eosinophil activation, causing tissue destruction (Liu et al. 
2013). Th17 can mediate glucocorticoid-resistant rejection (Nankivell and Alexander 
2010). One of the key mediators in autocrine T-cell activation is IL-2. CD4+ Th-cells 
also activate B-lymphocytes, CD8+ T-cells and macrophages (Liu et al.  2013).  
 
 
3.6.2 B-CELL ACTIVATION 
B-cells recognize foreign antigens via their B-cell receptors, which bind to antigen. 
They also require co-stimulation via cell-cell interactions or surrounding cytokines 
(Stegall et al. 2014). Once fully activated, B-cells proliferate and differentiate into 
antibody-secreting plasma cells or memory B-cells (Kim et al. 2014). Allo-antibodies 
secreted by these plasma cells may cause graft injury in various ways via complement 
system and by activating cytotoxic cells (Kim et al. 2014).  
 
3.7 REJECTION CLASSIFICATION AND SCORING 
 
3.7.1 BANFF CLASSIFICATION 
The Banff classification was created in the beginning of the 1990s to standardize the 
nomenclature and criteria for the diagnosis of rejection based on protocol biopsies 
(Solez et al. 1993). The Banff classification has been updated several times after its 
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original publication. In this classification system, renal biopsies are classified into six 
categories based on histopathological findings: normal, antibody-mediated changes, 
borderline changes, T-cell-mediated rejection, interstitial fibrosis, and tubular atrophy 
without specific etiology and changes not considered to be due to rejection. The Banff 
classification is routinely used in clinical transplantation to evaluate renal biopsies 
and originally introduced the term chronic allograft nephropathy (CAN), which was 
correlated with the term chronic allograft dysfunction or chronic rejection. CAN was 
introduced as a combination of several entities, including chronic rejection, 
calcineurin inhibitor (CNI) nephrotoxicity, and hypertensive changes. However, the 
term CAN was replaced in 2005 with the term "interstitial fibrosis and tubular atrophy 
without specific etiology" because CAN was considered to be used too liberally 
without attempting to specify the specific etiology (Solez et al. 2007). Therefore, 
aiming for a specific pathological diagnosis and terminology is currently 
recommended. However, this has led to somewhat arbitrary nomenclature and terms, 
such as chronic allograft injury (CAI) and chronic allograft dysfunction (CAD), 
which are used to describe multifactorial allograft dysfunction (Haas 2014).  
 
3.7.2 CADI SCORE 
The Chronic Allograft Damage Index (CADI) score is a sum of six parameters scored 
from 0-3, including interstitial inflammation and fibrosis, tubular atrophy, glomerular 
mesangial matrix increase, glomerular sclerosis, and arterial intimal proliferation 
(Isoniemi et al. 1992). The CADI criteria for inflammation and fibrosis are analogous 
with the Banff score so that inflammation scored 1, 2, and 3 with the CADI score is 
responding that of Banff score (interstitial fibrosis and total inflammation score in 
Banff 2007) (Solez et al. 2008). The CADI score is a numeric rejection score that 
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enables statistical comparisons between study groups. The score has been shown to 
predict the development of chronic rejection and outcome of kidney grafts in clinical 
kidney transplantation (Yilmaz et al. 2003). 
 
4. IMMUNOSUPPRESSIVE MEDICATION 
 
4.1 CORTICOSTEROIDS 
Corticosteroids have been used in kidney transplantation since the beginning of the 
modern era. These drugs suppress cytokine expression in a non-specific manner and 
affect T-cell activation and macrophage function (Borrows et al. 2004). High doses of 
corticosteroids are required in solid organ transplantation, which causes difficult side 
effects such as secondary diabetes, obesity, hypertension, and a Cushingoid 
appearance. Corticosteroids are currently used mainly as induction therapy and 
periodically in cases of acute rejection. Otherwise, steroid-sparing therapy is 
recommended. Good clinical results have been obtained with steroid-sparing 
regimens including Tac and MMF (Borrows et al. 2004). 
 
4.2 CALCINEURIN INHIBITORS 
Cyclosporine was introduced in the late 1970s and revolutionized solid organ 
transplantation (Calne et al. 1978). Cyclosporine inhibits calcineurin, which is a 
critical enzyme in T-cell signaling.  Without calcineurin, gene transcription of critical 
genes for T-cell activation, like IL-2, is suppressed (Camilleri et al.  2016). 
Cyclosporine has a narrow therapeutic window and multiple drug-drug interactions 
with other drugs because it effectively inhibits the CYP3A4 enzyme. Cyclosporine 
may cause nephro-, neuro-, and hepatotoxicity, affects lipid metabolism, and causes 
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hypertension (Gauthier and Helderman 2000) and hirsutism (Silva et al. 2014). In 
clinical transplantation, blood trough levels of cyclosporine are measured repeatedly 
to monitor the drug dose (Buchler et al. 2006). 
Another CNI, Tac, was introduced in 1987 (Kino et al. 1987). Clinical trials showed 
that Tac is more effective in preventing acute rejection than cyclosporine (Pirsch et al. 
1997). Tac also has a different side effect profile than cyclosporine, increasing the 
secondary diabetes rate compared to cyclosporine A (CsA), but it appears to have less 
cosmetic side effects (e.g., hirsutism) (Silva et al. 2014; Webster et al. 2005). In 
recent years, Tac has significantly increased its share as a primary CNI in renal 
transplant patients (Gardiner et al.  2016). Once-daily extended release Tac has 
increased patient compliance and reduced treatment failures because it has an easier 
dosage with a more consistent concentration profile (Bunnapradist et al. 2016). 
 
4.3 ANTIPROLIFERATIVE DRUGS  
Azathioprine (AZA) was widely used in kidney transplantation before CNIs were 
available. AZA is a non-specific antiproliferative drug that interferes with DNA 
synthesis and the function of various enzymes. AZA may cause side effects in rapidly 
proliferating tissues, such as bone marrow (Lennard et al. 1984). 
MMF inhibits de novo purine synthesis by competitively inhibiting inosine 5-
monophosphate dehydrogenase (IMPDH). Purine synthesis is needed in cell division 
(Platz et al. 1991). MMF suppresses T- and B-cell proliferation, clonal expansion, and 
the antigen-presenting capacity of dendritic cells. In addition, MMF decreases 
monocyte recruitment and, unlike CsA, is not fibrogenic (Allison and Eugui 2005). 
Instead, MMF appears to decrease graft fibrosis independent of its 
immunosuppressive mechanism (Mihovilovic et al. 2014). MMF also decreases acute 
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rejection (Ciancio et al.  2005) and graft loss (Knight et al. 2009; Wagner et al. 2015) 
compared to AZA in CNI combination regimens. 
SRL was introduced in the 1970s and investigated as an antifungal drug, but it was 
abandoned due to side effects. Twenty years later it was discovered that SRL has 
structural similarities with Tac (Sacks 1999). SRL affects T-cell expansion 
downstream of IL-2R activation and inhibits the proliferation of both T- and B-cells. 
In addition, SRL inhibits responses to growth factors bFGF, PDGF, VEGF, and TGF-
β (Morath et al. 2007). SRL has no nephrotoxic side effects but causes 
hyperlipidemia, anemia, edema, and an increased risk of cutaneous adverse effects 
(Woillard et al. 2012). SRL is currently being used in CNI-free immunosuppressive 
regimens that aim to prevent the nephrotoxic side effects of CNIs on kidney grafts. 
Everolimus (EVL) is an active metabolite of SRL (Morath et al. 2007). 
 
4.4 ANTIBODIES 
Specific immunosuppressive antibodies have been used in clinical transplantation to 
prevent acute rejection. Antibody therapy consists of repeated injections and may lead 
to anti-antibody production that decreases efficacy over time. Except for belatacept 
(see below), antibodies are mainly used in induction therapy and acute rejection 
episodes.  
Polyclonal anti-thymocyte globulin is used mainly in high-risk patients (Wagner and 
Brennan 2012). Basiliximab is a chimeric (mouse/human) monoclonal antibody for 
IL-2R on activated T-cells. Alemtuzumab is a humanized anti-CD52 antibody for 
surface antigen CD52 expressed on T and B-cells, as well as NK cells and monocytes. 
Alemtuzumab may be more efficient than other antibodies in preventing acute 
rejection (Zhang et al. 2012).  
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Belatacept is a fusion protein of human IgG and cytotoxic T-lymphocyte–associated 
antigen 4 (CTLA-4) that inhibits T-cell activation. It has been used in multidrug 
regimens instead of calcineurin inhibitors. Belatacept increases long-term patient and 
allograft survival, as well as graft function in clinical kidney transplantation compared 
to cyclosporine (Vincenti et al. 2016).     
 
5. CYTOKINES AND GROWTH FACTORS 
Cytokines are small soluble signaling proteins secreted by various cell types that act 
on other cells to change their function. These proteins mediate cell signaling and 
participate in various cellular adaptation processes, including immune and 
inflammatory responses (Dinarello 2007). Cytokines were originally named 
interleukins, chemokines, and lymphokines based, in part, on their discovery, but this 
nomenclature is somewhat arbitrary with regard to their function. Chemokines are 
small proteins that promote leukocyte migration into the allograft (O'Boyle, Ali et al.  
2011) and are named after their activity as chemotactic cytokines. Interleukins 
mediate, in part, antigen presentation and the effector phases of allo-specific immune 
responses. Also growth factors are cytokines. Cytokines have few common features 
and many of their other attributes may even be contradictory. The cytokine 
environment defines the effect of cytokines on target cells and tissues (Dinarello 
2007).  
 
5.1 PLATELET-DERIVED GROWTH FACTOR (PDGF) 
PDGF is a ubiquitous peptide that acts as a regulatory growth factor. It was originally 
discovered in the 1970s as a platelet-dependent serum factor that stimulates the 
proliferation of arterial smooth muscle cells (SMCs) in vitro (Ostendorf et al. 2014b; 
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Ross et al. 1974). Over-activation of PDGF is present in various tumor types, and its 
inhibition has been much studied in clinical oncology (Heldin 2013). Dimeric PDGF 
isoforms are composed of four different PDGF chains (A, B, C, and D). The A and B 
chains may unite to form three possible isoforms (PDGF-AA, PDGF-AB, PDGF-BB), 
whereas the PDGF-C and –D chains form homodimers (Ostendorf et al. 2014a). 
PDGF receptors (PDGFRs) consist of α and β subunits, which dimerize upon binding 
PDGF isoforms. PDGF-A and PDGF-C bind selectively to PDGFR-α, whereas the 
PDGF-B chain binds and dimerizes both PDGFR-α and PDGFR-β (Heldin et al.  
2002). PDGF-D binds specifically to PDGFR-β (Bergsten et al. 2001). PDGF is a 
very powerful inducer of mesenchymal cell proliferation and its role in the 
proliferation of mesangial cells in kidney diseases has been well-characterized both in 
vitro and in vivo (Ostendorf et al. 2014a). PDGF-B possibly plays a central role in 
mediating glomerular mesangial cell proliferation and has been demonstrated to be a 
potent mitogen and chemoattractant for renal mesangial cells (Floege et al.  2008). 
PDGF also stimulates extracellular matrix production by proliferating renal interstitial 
fibroblasts (Lu et al. 2016; Tang et al. 1996). PDGF ligands and receptors are induced 
during acute renal allograft rejection (Savikko et al. 2001a). Both experimental and 
clinical studies have shown that PDGF induction is associated with chronic rejection 
(Alpers et al. 1996; Savikko et al. 2002). In addition, in an experimental rat model, 
PDGF inhibition almost completely prevents chronic allograft nephropathy (Savikko 
et al. 2003). 
 
5.2 VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 
VEGF, previously known as vascular permeability factor, mediates both physiological 
and pathological angiogenesis and increases vascular permeability (Leung et al. 
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1989). In the early 1980s, VEGF was found to be a protein that induces vascular 
leakage (Ferrara 2009; Senger et al. 1983). Neo-angiogenesis enables tumor growth 
and VEGF plays a profound role in tumor neo-angiogenesis; therefore, its inhibition 
has been studied extensively in clinical oncology (Arjaans et al. 2016). Four different 
VEGF proteins (VEGF-A, -B, -C, and -D) have been described (Yamada et al. 1997). 
These proteins differ in their affinities to three VEGF receptors (VEFGRs); VEGFR-
1, -2, and -3 are all RTKs (Claesson-Welsh 2016). In experimental kidney 
transplantation, VEGF expression is increased during both acute and chronic rejection 
(Malmstrom et al. 2008). 
 
5.3 TRANSFORMING GROWTH FACTOR BETA (TGF-β) 
TGF-β is present in serum, platelets, and macrophages and was found in the early 
1980s to be an inducer of rapid fibroblast growth (Assoian et al. 1983). TGF-β plays a 
crucial role in the initiation, development, and metastasis promotion of various 
tumors. Its inhibition is an emerging intervention in clinical oncology, though it 
appears to have differential effects during different stages of carcinogenesis (Neuzillet 
et al. 2015). TGF-β activation has a key role in the fibrotic process of chronic kidney 
diseases (Vega et al.  2016). It induces cell proliferation in fibroblasts and causes 
mesenchymal cell matrix deposition through the promotion of extracellular matrix-
associated gene expression and suppression of the activity of genes encoding matrix 
metalloproteinases, which degrade extracellular matrix (Border and Noble 1994; 
Leask and Abraham 2004; LeRoy et al. 1990; Liu et al. 2016). Serum TGF-β is 
mainly found in its inactive form associated with serum proteins and is activated by 
proteolytic cleavage (Annes et al.  2003). TGF-β in the renal interstitium is secreted 
by macrophages and causes the infiltration and activation of monocytes via monocyte 
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chemoattractant protein-1 (MCP-1) (Wang et al. 1999). TGF-β also causes the tubular 
epithelial to mesenchymal cell transition in which renal tubular cells transform into 
fibroblasts, and even further into myofibroblasts, which cause interstitial matrix 
accumulation and subsequent renal fibrinogenesis (Cho et al. 2016; Iwano and 
Neilson 2004). Elevated serum TGF-β concentration (Baczkowska et al. 2005) and 
renal tissue expression (Viklicky et al. 2003) has been shown to correlate with 
histological changes in chronic rejection. In addition, elevated urinary TGF-β 
concentrations in renal transplant recipients have been reported to correlate with 
proximal tubular injury (Teppo et al. 2004) and decreasing allograft function 
(Sibunruang et al. 2015).  
 
5.4 EPIDERMAL GROWTH FACTOR (EGF) 
EGF has various in vitro effects on both epithelial and mesenchymal cells; it promotes 
cell proliferation (Carpenter and Cohen 1976), chemotaxis (Blay and Brown 1985), 
and mitogenesis (Sherline and Mascardo 1982). EGF was found in the early 1960s as 
an inducer of mouse eyelid opening due to epidermal growth and keratinization 
(Cohen 1962). Over-expression of EGF is a common feature in various tumor types 
and its inhibition is used clinically to treat malignant diseases (Zeng and Harris 2014). 
EGF exerts its effects through its specific RTK and participates in multiple signal-
transduction pathways. The protein also has various renal effects and may play a role 
in the development of diabetic nephropathy (Saad et al. 2005; Wassef et al.  2004). 
Furthermore, EGF decreases the glomerular filtration rate (Harris et al. 1988) and 
EGF receptor (EGFR) is an important mediator of renal endothelial dysfunction 
(Helle et al. 2009). According to microarray study of transplant biopsies, both EGF 
gene and protein expression is increased during allograft injury (Dosanjh et al. 2013) 
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In addition, inhibition of EGF has been shown to ameliorate experimental chronic 
renal fibrosis (Francois et al. 2004).  
 
5.5 GROWTH FACTOR INTERACTIONS 
Growth factors have wide range of interactions that modify their responses and effects 
(Figure 1). PDGF increases the sensitivity of fibroblasts to EGF activity (Wharton et 
al. 1983) and EGFR expression is critical for PDGF-induced fibroblast migration, 
suggesting a common downstream interaction (He et al. 2001; Li et al. 2000). 
Furthermore, PDGF mediates the interaction of TGF-β and EGF (Andrianifahanana et 
al. 2013). PDGF also induces VEGF (Hou et al. 2010), VEGFR (Edelberg et al. 1998; 
Stavri et al. 1995), TGF-β (Nishishita and Lin 2004), and bFGF (Sato et al. 1991), 
though PDGF-BB and bFGF interact directly, which appears to decrease their 
mitogenic activity (Russo et al. 2002). However, PDGF induces intercellular high 
molecular weight bFGF formation (Pintucci et al. 2005), which induces VEGF 
expression and mediates bFGF-VEGF interactions (Seghezzi et al. 1998). 
Furthermore, PDGF and bFGF have additive effect on chemotaxis (Ucuzian et al. 
2010). EGF induces TGF-β expression (Qian et al. 2016; Van Obberghen-Schilling et 
al. 1988) and interacts with TGF-β in mediating the mitogenic effects on fibroblasts 
(Brinckerhoff 1983), renal fibrosis (Chung et al. 2013; Liu et al. 2015) and EMT 
(Docherty et al. 2006). EGF also induces VEGF (Frank et al. 1995; Kang et al. 2016) 
and has synergistic interactions with bFGF (Takeuchi et al. 1992). TGF-β induces 
EGFR expression (Assoian et al. 1984), as well as VEGF (Pertovaara et al. 1994; 
Suzuki et al. 2012) and bFGF (Finlay et al. 2000; Strutz et al. 2001) which also 
induces TGF-β. VEGF and FGF have synergistic effect in inducing PDGF (Kano et 
al. 2005). 
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Due to these interactions, growth factor expression may intensify after it is initiated 
and may be prolonged even after the initial cause has been excluded. These growth 
factor interactions are emphasized by the finding that growth factors may also 
intensify their own signaling cascades via autocrine loops, as shown with EGF 
(DeWitt et al. 2001; Earp et al. 1986), VEGF (Uchida et al. 1994; Vega-Diaz, Herron 
et al.  2001), bFGF (Miyamoto et al. 1998; Weich et al. 1991), TGF-β (Van 
Obberghen-Schilling et al. 1988), and PDGF (Eriksson et al. 1991; Sabuda-
Widemann et al. 2009). 
 
FIGURE 1: Growth factors have multiple interactions with other growth factors 
that may modulate the outcome of cytokine expression (red arrow and + 
represents inducing effect and yellow arrow and syn. represents syngenic effect. 





5.6 GROWTH FACTORS IN END-STAGE RENAL DISEASE 
PDGF expression is increased in diabetic nephropathy (Boor et al.  2014; Langham et 
al. 2003), and elevated urinary PDGF excretion correlates with the progression of 
nephropathy (Wang et al.  2009). In addition, VEGF (Bailey et al. 1999; Shao et al. 
2016), TGF-β (Mou et al. 2016; Yamamoto et al. 1993), EGF (Chen et al.  2015; 
Gilbert et al. 1997), and bFGF (Vasko et al. 2009) are induced and active during 
diabetic nephropathy. Inhibition of PDGF (Lassila et al. 2005), VEGF (Sung et al. 
2006), and TGF-β (Ziyadeh et al. 2000) has been shown to prevent histological 
changes in diabetic nephropathy, suggesting their causative role in the development of 
the disease. 
In clinical glomerulonephritis, the expression of PDGF (Boor et al. 2014), TGF-β 
(Meng et al. 2014; Niemir et al. 1995), EGF (Bollee et al. 2011; Nakopoulou et al. 
1994), and VEGF (Hohenstein et al. 2010) is increased. Evidence of increased bFGF 
expression and the benefits of bFGF inhibition in experimental glomerulonephritis 
have also been shown (Floege et al. 1998). In addition, inhibition of PDGF prevents 
experimental renal changes in glomerulonephritis (Iyoda et al. 2009).  
The expression of PDGF (Liapis et al. 1997), VEGF, EGF, bFGF (Song et al. 2009), 
and TGF-β (Chea and Lee 2009) is increased in polycystic renal disease. In 
hypertensive nephrosclerosis, TGF-β is induced (Razzaque et al.  1996) and has been 
suggested to play a role in renal amyloidosis (Danilewicz and Wagrowska-Danilewicz 
2006). 
Diabetes is a major risk factor for cardiovascular diseases and diabetic nephropathy is 
one of the main indications for kidney transplantation. Inhibition of PDGF and VEGF 
has been shown to induce remission in diabetes (Templeton et al. 2008). In addition, 
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inhibition of PDGF appears to prevent both diabetic nephropathy and diabetes-
associated atherosclerotic vascular lesions (Lassila et al. 2004; Lassila et al. 2005). 
Furthermore, inhibition of PDGF appears to limit the progression of chronic kidney 
disease in an experimental 5/6 nephrectomy model (Iyoda et al. 2011). 
In summary, pathological growth factor expression is seen before and during the 
development of ESRD. This prolonged growth factor expression may affect 
subsequent development of rejection changes, as growth factor expression is already 
increased before kidney transplantation. Interestingly, growth factor inhibition has 
been shown to decrease the development of diseases that are primary reasons for 
ESRD and subsequent renal transplantation. 
 
5.7 GROWTH FACTORS IN TRANSPLANTATION 
ESRD patients are in a dual state of activated innate immunity, which may strengthen 
immune responses, and acquired immunosuppression, which may impair innate 
immunity (Anders et al.  2013). This dual state may affect the innate immune 
response in renal transplantation patients. Innate immunity has been shown to induce 
growth factor expression in patients with diabetes (Fischetti et al. 2011). VEGF also 
appears to activate NK cells (Cervi et al. 2007), and the inhibition of VEGFR blocks 
innate immunity-derived NK cell recruitment in animal models of cancer (Doloff and 
Waxman 2012). In addition, ischemia reperfusion injury induces growth factor 
expression (Spurgeon et al.  2005). 
Growth factors also stimulate adaptive immunity and allo-recognition. PDGF and 
EGF stimulate T-cell proliferation and MHCII expression on APCs (Acres et al. 
1985) and PDGF-inhibition decreases the differentiation of dendritic cells (Appel et 
al. 2004). T-cells express TGF-β, and this expression is significantly increased upon 
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T-cell activation (Kehrl et al. 1986). In addition, T-cell activation stimulates their 
VEGF expression, which is otherwise quiescent (Iijima et al.  1996). VEGF stimulates 
plasma cell proliferation (Rodriguez-Bayona et al. 2013). Macrophages secrete 
various growth factors, including PDGF, VEGF, TGF-β, and bFGF (Shimokado et al. 
1985; Sunderkotter et al. 1994); their PDGF secretion is stimulated by IL-2 (Kovacs 
et al. 1994).   
Human cytomegalovirus (CMV) infection is a frequent complication after kidney 
transplantation, with up to 26% of renal transplant patients infected during the first 
year after transplantation (Erdbrugger et al. 2015). CMV infection increases both graft 
loss and all cause mortality (Erdbrugger et al. 2015). EGFR plays an important role in 
both the mediation of viral entry into human monocytes and monocytic migration 
required for viral spreading (Chan et al. 2009). 
Immunosuppressive drugs differ in their effects on growth factors. Cyclosporine has 
been shown to induce macrophage PDGF-B production in vitro (Iacopino et al. 1997). 
In addition, cyclosporine induces EGF (Chin et al. 2006) and TGF-β expression both 
in vitro and in vivo (Khanna et al. 1994, Shin et al. 1998), which may mediate the 
long-term nephrotoxic side effects of cyclosporine (Khanna et al. 1999). However, 
CsA appears to inhibit VEGF (Maruyama et al. 1992). Tac also induces TGF-β 
expression (Bennett et al. 2016; Khanna et al. 1999), but the in vitro effects of Tac 
have been investigated less than those of CsA. At least in hepatocytes, Tac has no 
effect on EGF and VEGF expression (Escribano et al. 2002; Serrano et al. 2006). SRL 
inhibits PDGF and bFGF-induced fibroblast proliferation in vitro (Salas-Prato et al. 
1996) and is a known inhibitor of VEGF (Laugharne et al. 2007). However, SRL also 
induces TGF-β (Dodge et al. 2000). 
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 According to experimental models, growth factor expression is induced in rejecting 
allografts (Savikko et al. 2001b) and, according to clinical studies, elevated serum 
VEGF levels predict the development of rejection in both cardiac (Aharinejad et al. 
2009) and renal transplantation (Peng et al. 2008). Exogenous adenovirus-derived 
TGF-β (Csencsits et al. 2006), PDGF (Tuuminen et al. 2009), and VEGF (Lemstrom 
et al. 2002) induce chronic rejection in experimental cardiac transplantation models. 
Inhibition of TGF-β with anti-TGF-β antibody prevents chronic renal rejection (Guan 
et al. 2013). Furthermore, inhibition of PDGF has been shown to prevent chronic 
rejection in a rat model (Savikko et al. 2003). According to these results, growth 
factors are induced in rejecting allografts, cause rejection when used exogenously, 
and prevent rejection when inhibited. Therefore, growth factors appear to play a 
significant role in the development of the rejection process. 
In summary, increased growth factor expression in solid organ transplantation is 
initiated by multiple pathways that are unaffected by immunosuppressive medications 
or induced by them. Early events such as ischemia reperfusion injury, innate 
immunity, allo-recognition, or T-cell activation may induce growth factors despite 
immunosuppressive medication. As growth factors induce their own expression, as 
well as the expression of other growth factors via interactions, this cascade may lead 








6. TYROSINE KINASE INHIBITION 
 
6.1 TYROSINE KINASES AS GROWTH FACTOR RECEPTORS  
RTKs are membrane-bound molecules that mediate growth factor signals from the 
cell surface to the intracellular space, leading to a growth factor response (Lemmon 
and Schlessinger 2010). In contrast, cytoplasmic tyrosine kinases mediate intracellular 
cascades. RTKs consist of an extracellular N-terminal ligand binding domain, a 
transmembrane domain, and intracellular C-terminal domain with tyrosine kinase 
activity. Upon ligand binding, RTKs undergo lateral dimerization in the membrane 
plane. These dimers have catalytic activity that leads to autophosphorylation of the 
RTK dimers in the intracellular domains. This phosphorylation then triggers signaling 
events (Hubbard and Miller 2007). In addition, RTKs have multiple additional 
phosphorylation sites for response modulation and interactions (Lemmon and 
Schlessinger 2010). 
RTKs are structurally similar, and several subgroups exist, such as EGFRs, fibroblast 
growth factor receptors, insulin-like growth factor receptors, PDGFRs, and VEGFRs. 
Approximately 60 different RTKs are known, and many of them are growth factor 
receptors (Vlahovic and Crawford 2003). 
 
6.2 TYROSINE KINASE INHIBITORS 
Pathological growth factor expression is a common feature in various cancers and a 
possible point of intervention. Therefore, vast resources have been used to develop 
growth factor-inhibiting drugs. Imatinib was the first oral TKI that revolutionized the 
treatment of chronic myeloid leukemia (Druker et al. 2001). Several other TKIs that 
inhibit different RTKs have followed (Broekman et al. 2011). TKIs are administered 
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orally once or twice daily, and their effect is achieved by competitive inhibition of 
intracellular ATP binding on the RTK. TKIs differ in their selectivity. Some TKIs are 
called pan-TKIs or multi-target TKIs because they inhibit several RTKs, whereas 
others are more selective (Broekman et al. 2011).  
TKIs inhibit several signaling cascades and, especially pan-TKIs, may interfere with 
physiological cell signaling. However, TKIs are considered to be well tolerated in 
clinical oncology. In the field of transplantation, the acceptable level of adverse 
effects is certainly lower than in the treatment of malignancies. However, tyrosine 
kinases are increasingly being investigated outside oncology and are considered for 
use even in renal autoimmune diseases (Wallace and Gewin 2013). Therefore, they 
could be considered in transplantation regimens. 
 
6.2.1 FK778 
Leflunomide (LFM) is used as an immunosuppressant in rheumatoid arthritis. It has 
potent immune-modulatory and anti-inflammatory effects but a long half-life that has 
restricted its use as an immunosuppressant. FK778 is an analogue of the active 
metabolite of LFM. With a shorter half-life than LFM, FK778 could be a more useful 
choice in solid organ transplantation (Fitzsimmons and First 2004; Vanrenterghem et 
al. 2004). Similar to LFM, FK778 inhibits T- and B-cell proliferation and interferes in 
de novo pyrimidine biosynthesis by inhibiting the dihydro-orotate dehydrogenase 
(Fitzsimmons and First 2004). Additional immunosuppressive effects of LFM and 
FK778 are achieved by the inhibition of several growth factor RTKs, such as EGF 
and VEGF, which have been shown to be inhibited by LFM in vitro (Bartlett et al. 
1991; Shawver et al. 1997). LFM also inhibits PDGF RTK activity and strongly 
inhibits the growth of PDGFR-overexpressing glioma in vivo (Xu et al. 1999). FK778 
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decreases neointimal proliferation and is thus vasculoprotective independent from 
dihydro-orotate dehydrogenase inhibition (Savikko et al.  2003). FK778 also reduces 
endothelial adhesion molecule upregulation and attenuates lymphocyte-endothelium 
interactions both in vitro and in vivo (Deuse et al. 2004; Schrepfer et al. 2005).  
 
6.2.2 IMATINIB 
Imatinib, an orally administered RTK inhibitor, is well known as the first small 
molecule inhibitor of tyrosine kinases to be licensed for cancer treatment. Imatinib 
inhibits PDGF RTK (Buchdunger et al. 2000). Imatinib has been shown to inhibit 
both PDGF-α and -β receptors (Buchdunger et al. 2000). It has also been 
demonstrated to inhibit TGF-β signaling via a non-Smad TGF-β pathway (Wang et al. 
2005).  
In clinical oncology, imatinib has been shown to be well-tolerated and effective in the 
treatment of chronic myeloid leukemia and gastrointestinal stromal tumor (Joensuu et 
al. 2013; Yeung et al. 2015). The most frequent adverse effects of imatinib are fluid 
retention, abdominal disorders, skin rash, and hematological disorders (anemia, 
neutropenia, and thrombocytopenia). In long-term oncological usage, only 21.8% of 
patients have grade 3-4 adverse effects (National Cancer Institute common toxicity 
criteria, indicating severe or life-threatining adverse effect)  (Kalmanti et al. 2015). 
In addition to approved indications, trials have suggested that imatinib has efficacy 
against desmoid tumors (Chugh et al. 2010), pulmonary manifestations of systemic 
sclerosis (Fraticelli et al. 2014), and recurrent dermatofibrosarcoma (Ugurel et al. 
2014). A combination of imatinib with traditional chemotherapy may offer antitumor 
activity in metastatic solid tumors, such as breast cancer and soft-tissue sarcomas 
(Pishvaian et al. 2012), as well as advanced endocrine tumors (Halperin et al. 2014). 
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Interestingly, imatinib has efficacy against steroid-refractory graft versus host disease 
after stem cell transplantation (Olivieri et al. 2013). 
Case studies have suggested that imatinib may be effective against Crohn´s disease 
(Magro and Costa 2006) and rheumatoid arthritis (Pereira et al. 2010). Based on 
various immunomodulatory findings, imatinib has been suggested as a treatment for 
immune-mediated kidney injury (Wallace and Gewin 2013). 
Experimental data suggest that imatinib may have a beneficial effect against 
neurobehavioral deterioration after subarachnoid hemorrhage (Shiba et al. 2013) and 
multiple sclerosis (Adzemovic et al. 2013). In addition, imatinib prolongs the time-
frame for thrombolytic treatment after stroke (Su et al. 2008) and attenuates 
experimental forms of diabetic nephropathy (Lassila et al. 2005) and diabetic 
atherosclerosis (Lassila et al. 2004). 
 
6.2.3 ERLOTINIB 
Erlotinib is a highly selective, novel oral TKI for EGFR (Pollack et al. 1999). The 
concentration required to inhibit PDGF is >1000-fold that needed for EGF inhibition 
(Pollack et al. 1999). Erlotinib is clinically used for non-small cell lung cancer and 
pancreatic cancer, and it prolongs progression-free survival in both of these 
malignancies (Cappuzzo et al. 2010, Moore et al. 2007). Based on clinical trials, 
erlotinib is well tolerated, and only 16% of patients required a dose reduction; the 
main adverse effects were skin rash and diarrhea (Neal 2010). In addition, preliminary 
reports indicated that erlotinib may have efficacy against myelodysplastic syndrome 
(Thepot et al. 2014), as well as against head and neck cancer (Rosenthal et al. 2014). 
Experimentally, erlotinib inhibits the development of dysplastic lesions in colon 




Sunitinib is a TKI for gastrointestinal stromal tumor (GIST) and metastatic renal cell 
carcinoma (Chow and Eckhardt 2007). It inhibits PDGFR-α and –β and VEGFR-1, -2, 
and -3 at similar concentrations (Mendel et al. 2003). Sunitinib has been used 
successfully in the treatment of imatinib-resistant tumors, which indicates better 
efficacy, although the effect is at least partly dependent on the genetic factors of the 
tumor (Heinrich et al. 2008). However, sunitinib is more effective than imatinib in 
preventing PDGFR-β phosphorylation (Abrams et al. 2003). Efficacy against 
differentiated thyroid cancer (Bikas et al. 2016), advanced melanoma (Decoster et al. 
2015), recurrent endometrial carcinoma (Castonguay et al. 2014), and aggressive 
fibromatosis has also been reported (Jo et al. 2014). 
Sunitinib appears to increase glucose control in type 2 diabetes patients (Oh et al. 
2012) and, according to a case study, even individual type 1 diabetes patients may 
benefit from sunitinib (Huda et al. 2014). Interestingly, sunitinib may interfere with 
innate immunity via reductions in cytokine levels (Jha et al. 2011). 
Sunitinib inhibits various tyrosine kinases and has a wider range of adverse effects 
than imatinib or erlotinib. The most frequent side effects are diarrhea, fatigue, and 
nausea. Hypertension, hand and foot syndrome (dysesthesia and tingling of the palms, 
fingers and soles of the feet), and hematological adverse effects are also rather 
common. Fifty-two percent of patients have grade 3 or 4 adverse effects during the 
first year of sunitinib treatment, but after that the adverse effects steadily decrease, 
except for hypothyroidism which had a cumulative incidence of 36% over 6 years 




AIMS OF THE STUDY 
The aim of this study was to investigate different TKIs and their effect on growth 
factor expression and the development of acute and chronic rejection in an 
experimental rat kidney transplantation model. 
 
The specific aims of this study were: 
1. To investigate the effect of FK778 on acute and chronic rejection in both 
monotherapy and combination therapy with cyclosporine and tacrolimus. 
2. To investigate the effect of FK778 on post-transplant growth factor 
expression. 
3. To investigate whether short-term imatinib treatment is sufficient to prevent 
later chronic rejection changes in kidney grafts. 
4. To investigate the effect of EGF inhibition with erlotinib on acute rejection 
and the development of chronic rejection. 
5. To investigate the effect of combined inhibition of PDGF and VEGF with 







1. EXPERIMENTAL STRATEGY 
Our aim was to investigate the effect of various human drugs in an experimental 
kidney transplantation model of chronic rejection. Because acute rejection is a major 
reason for the development of chronic rejection, we used a 5-day transplantation 
model to investigate early events and acute rejection and a 90-day transplantation 
model to investigate chronic rejection. Right-side nephrectomy was performed during 
the primary operation and a left-side nephrectomy after week 1. From weeks 2 to 12. 
the chronic study groups were dependent on the transplanted kidney graft for their 
renal function. During the longer study period, we obtained weekly blood samples to 
measure serum creatinine as an indication of graft function. 
Many of the drugs used in our experiments were originally tested by their developers 
in mouse models, and ready-to-use doses for rat studies could not be taken from the 
literature. Therefore, we performed dose-response studies with an experimental rat 
aorta denudation model (III and IV) to define drug doses that could be used in a more 
demanding and time-consuming transplantation model. The denudation model also 
mimics transplant vasculopathy, offering new knowledge on the effects of these 
drugs. Because cellular pathways that mediate the effect of TKIs on the rejection 
process are somewhat unclear, we also performed vitro studies to investigate the 
effect of sunitinib on SMCs (IV). Histological results were analyzed by the CADI 
score and immunohistochemistry was used to define growth factor expression in 




2. EXPERIMENTAL ANIMALS 
Male Wistar rats (Harlan, the Netherlands) weighing 350 to 370 g were used for aorta 
denudation. Specific, pathogen-free, inbred male Wistar Furth (WF; RT1u) and Dark 
Agouti (DA; RT1a) rats (Harlan, the Netherlands) weighing 300–350 g were used for 
renal transplantation. These inbred rat strains have a well-defined major MHC-
mismatch that results a severe mixed interstitial-vascular type acute rejection with 
tubular and glomerular necrosis by day 7 unless treated with immunosuppressive 
regimen (Savikko et al. 2001a). All animal surgeries were performed using isoflurane 
(Baxter, Deerfield, IL) induced anesthesia. The rats received regular rat food and tap 
water ad libitum and were maintained on a 12-h light/dark cycle. Buprenorphine 
(Temgesic; Reckitt & Colman, Hull, England) was used for postoperative pain relief. 
The animals received human care in compliance with the Guide for the Care and Use 
of Laboratory Animal Resources published by the National Institutes of Health and 
Office of Animal Care and Use (National Research Council, Washington, DC, 
National Academy Press 1996).  
 
3. RAT AORTA DENUDATION MODEL 
The aortas were denuded of endothelium by intraluminal passage of a size 2 French 
Fogarty arterial embolectomy catheter (Baxter Healthcare Corporation, Santa Ana, 
CA) introduced through the left iliac artery during isoflurane-induced anesthesia. The 
rats were orally treated with erlotinib (1, 5, or 10 mg/kg/d; Roche, Basel, 
Switzerland), sunitinib (1, 5 or 20 mg/kg/d; Phizer, New York, NY) or vehicle only 
(polyethylene glycol) once a day. Aortic samples were harvested 14 days after injury 
and histological changes and the size of the neointimal area evaluated from midaortic 
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sections. The neointimal area was digitally analyzed using Axioplan 4.2 analysis 
software (Carl Zeiss, Oberkochen, Germany). 
 
4. EXPERIMENTAL KIDNEY TRANSPLANTATION IN RATS 
Transplantations were performed from DA to WF rats using a modified microsurgical 
technique (Savikko, Kallio et al. 2001a, Fisher and Lee 1965). Syngenic 
transplantations from DA to DA rats were used as controls. The donor kidney was 
transplanted heterotopically to the recipient´s abdominal aorta and inferior vena cava 
using an end-to-side aortic and vena caval anastomosis. Uretral anastomosis was 
performed end-to-end close to the renal pelvis. The right native kidney was removed 
during transplantation and a left nephrectomy performed postoperative day 7 for 
animals in chronic rejection groups. In the acute rejection groups, the left kidney was 
left in situ because the animals were allowed to recover from the primary operation. 
The total perioperative ischemia time was standardized between 50 and 60 min, 
beginning with exsanguination and cold perfusion of the graft and ending with 
revascularization of the graft.  
Rats were medicated daily via lavage (per orally) or needle (subcutaneusly) by 
researchers and their overall condition and behavior checked during the medication 
process. In addition, all study animals were checked daily by independent animal 
specialists to monitor their well-being.  
 
5. DRUG REGIMENS 
After transplantation, the rats were medicated once daily. Buprenorphinum 
(Temgesic; Reckitt & Colman, Hull, England) was used for postoperative pain relief 
after transplantation and after nephrectomy in the chronic groups. 
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CsA (Sandimmun, Novartis, Basel, Switzerland) was purchased from the local 
hospital pharmacy, dissolved in intralipid (Kabi Vitrum, Stockholm, Sweden) to a 
final concentration of 1.5 mg/ml, and administrated subcutaneously. Tac (kindly 
provided by Fujisawa, Osaka, Japan) was dissolved in distilled water to a final 
concentration of 1.5 mg/ml and administrated orally. FK778 (kindly provided by 
Fujisawa) was dissolved in 1% carboxymethyl cellulose to a final concentration of 5 
or 10 mg/ml and administrated orally. Imatinib (Glivec, Novartis) was purchased 
from the local hospital pharmacy, dissolved in water to a final concentration of 10 
mg/ml, and administered orally once a day. 
Erlotinib (kindly provided by Roche) was dissolved in polyethylene glycol (Sigma-
Aldrich, St. Louis, MO) and administered orally daily at 10 mg/kg/d. Sunitinib 
(kindly provided by Pfizer) was dissolved in polyethylene glycol (Sigma-Aldrich) to a 
final concentration of 2 mg/ml. 
For acute rejection experiments, rats were treated with a monotherapy of CsA (1.5 
mg/kg/d), Tac (1.5 mg/kg/d) or FK778 (5, 10 or 20mg/kg/d, I) or with a combination-
therapy of CNI (CsA or Tac) and FK778 (10mg/kg/d, I), erlotinib (10mg/kg/d, II) or 
sunitinib (2mg/kg/d, IV). In chronic rejection experiments CNI (CsA or Tac) was 
used as a monotherapy or combined with FK778 (10mg/kg/d, I), imatinib (10mg/kg/d, 
II), erlotinib (10mg/kg/d, III) or sunitinib (2mg/kg/d, IV). 
 
6. HISTOLOGY 
Histological staining was done to enable histological evaluation of rejection changes 
using the CADI score. 
The kidney grafts were bisected horizontally and fixed in 4% paraformaldehyde. The 
specimens were cut into 2-µm-thick sections and stained with Mayer’s hematoxylin-
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eosin (HE), Masson’s trichrome, and diastase-periodic acid-Schiff (D-PAS) to 
investigate chronic rejection changes. 
Histopathological analysis was done in a blind review. To investigate acute rejection, 
the intensity of perivascular and diffuse interstitial inflammation was scored in the 
samples as follows: 0, no inflammation; 1, faint inflammation; 2, moderate 
inflammation; and 3, intense inflammation. Chronic rejection changes were scored 
according to the CADI, which consists of six parameters scored from 0-3, including 
interstitial inflammation and fibrosis, tubular atrophy, glomerular mesangial matrix 
increase, glomerular sclerosis, and arterial intimal proliferation. The CADI grading of 
fibrosis and tubular atrophy from 1-3 is analogous to the Banff score (Banff 2009, 
category 5 grades I, II, and III) (Sis et al. 2010). The CADI score is a numeric 
rejection score that enables statistical comparisons between study groups. 
  
7. IMMUNOHISTOCHEMISTRY 
Immunohistochemical staining was used to define post-transplant growth factor 
expression and localization. The samples were incubated in 4% paraformaldehyde for 
4 h and then routinely fixed in paraffin blocks. Sections (4-µm-thick) were cut in 
series on glass slides. Before staining, the samples were deparaffinized. For epitope 
retrieval, the glass slides were heated in a microwave oven for 20 min in sodium 
citrate buffer (pH 6.0) and then allowed to cool to room temperature for 20 min. To 
demonstrate the expression and localization of growth factors, the samples were 
immunostained using the Vectastain Elite ABC Kit (Vector Laboratories Inc., 
Burlingame, CA) or the EnVision™ G|2 System/AP, Rabbit/Mouse (Permanent Red) 
kit (Dako Systems, Glostrup, Denmark) according to the manufacturer´s instructions. 
The final staining reaction was revealed by NovaRed (Vector Laboratories) according 
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to the manufacturer´s instructions, yielding a red reaction product. After staining, the 
slides were counterstained with Mayer’s hemalum and permanently mounted after 
incubation in alcohol series and xylene. Negative controls without primary antibody 
were used for all staining experiments. 
Polyclonal goat IgG antibody to PDGF-A (2 µg/ml, sc-128, Santa Cruz 
Biotechnology, Inc., CA), PDGF-B (5 µg/ml Abcam, Cambridge, UK), PDGFR-α (10 
µg/ml, Lab Vision Corp, Fremont, CA), PDGFR-β (2 µg/ml, Santa Cruz), VEGF-A (2 
µg/ml; Santa Cruz), VEGF-B (2 µg/ml; Santa Cruz), VEGFR-1 (2 µg/ml; Santa 
Cruz), VEGFR-2 (2 µg/ml; Santa Cruz), TGF-β (2 µg/ml, Santa Cruz), TGF-βR1 (2 
µg/ml, Santa Cruz),  EGF (200 µg/ml; sc-1343; Santa Cruz), and EGF-R (200 µg/ml; 
sc-03, Santa Cruz) were purchased from commercial suppliers. 
Immunohistochemical analysis was done in a blind review. The intensity of the 
staining was scored in the samples as follows: 0, no visible staining; 1, cells with faint 
staining; 2, moderate intensity with multifocal staining; and 3, intense diffuse 
staining. 
  
8. IN VITRO STUDIES 
In vitro studies of SMC proliferation were performed to investigate the pathway that 
could mediate the effect of TKIs on the histological rejection process. Rat coronary 
artery SMCs (kindly provided by Professor Dariusz Leszczynski; Finnish Centre for 
Radiation and Nuclear Safety, Helsinki, Finland) were cultured in DMEM 
(Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS), 1% glutamine 
(Invitrogen), and 2.5% penicillin and streptomycin (Invitrogen). For the proliferation 
study, 500 cells were cultured in 96-well culture plates for 24 h following 72 h in 
serum-free media. After serum starvation, the cells were stimulated to proliferate with 
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2 ng/ml of rat recombinant PDGF-BB (Sigma-Aldrich, St. Louis, MO), a known SMC 
inductor (Nykanen et al. 2005). Unstimulated cells were used as a control group to 
reveal the stimulation effect. After stimulation, the cells were treated with sunitinib 
(1, 2, or 5 nM) or left untreated. Sunitinib was dissolved in dimethyl sulfoxide 
(DMSO; Sigma-Aldrich). After a 24-hour stimulation, the cell proliferation was 
counted by visual cell count. Cell proliferation index was calculated according to 
proliferation results.  
Smooth muscle cell migration was quantitated in Transwell culture chambers 
(Corning Inc., Corning, NY) where the up- per and lower culture chamber are 
separated by a polycar- bonate filter with 8-μm pores. The chambers were first coated 
with collagen (Rat Tail Collagen, Type 1, Sigma- Aldrich) at a concentration of 20 
μg/mL at +4°C for 24 hours. Rat coronary artery SMC were seeded in the upper 
chamber. The PDGF-B was added to the lower chamber in Dulbecco's Modified 
Eagle Medium supplemented with 0.5% FCS and 0.1% BSA. The cells were treated 
with sunitinib (0.05, 0.1 or 0.2 μM) dissolved in dimethyl sulfoxide (Sigma) or left 
untreated. After 24 hours, the filters were removed, fixed with methanol, and stained 
with Mayers hematoxylin-eosin. Migrated cells (on the lower side of the filter) were 
quantitated by counting specified cross-sectional fields with a light micro- scope 
using 400 magnification. The in vitro experiment was repeated three times and was 
done in triplicates.  
  
9. STATISTICAL ANALYSIS 
The results are expressed as mean±SE. P<0.05 was accepted as significant. 
Significant differences between groups were determined by parametric analysis of 
variance and the least significant difference test, ANOVA, or Mann-Whitney non-
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parametric analysis (SPSS, Chicago, IL). Serum creatinine levels between groups 










1. CLINICAL COURSE  
All drugs studied were well tolerated. No adverse effects were observed and the 
overall condition of study animals and their behavior were normal in all study groups 
throughout the observation period (I-IV). 
 
2. THE EFFECT OF ERLOTINIB AND SUNITINIB ON NEOINTIMAL 
FORMATION  
Aortic denudation with an embolectomy catheter resulted in moderate asymmetric 
neointimal formation in the vehicle-treated group at day 14 (III and IV). Erlotinib 
ameliorated this neointima formation in a dose-dependent manner starting from 5 
mg/kg/d (III). Sunitinib also had a dose-dependent effect on preventing neointima 
formation (IV). A significant reduction in the neointimal area was observed with a 
sunitinib dose of 1 mg/kg/d, and neointimal formation was almost completely 
prevented with 5 mg/kg/d and 20 mg/kg/d (IV). 
 
3. THE EFFECT OF SUNITINIB ON SMC PROLIFERATION AND MIGRATION  
PDGF-B is known to induce SMC proliferation in vitro and caused a 2.7-fold increase 
in SMC proliferation when compared to non-stimulated SMCs (IV). Sunitinib reduced 
SMC proliferation in a dose-dependent manner, and the highest concentrations 
completely prevented SMC proliferation  (IV). 
The PDGF-B induction caused a 2.8-fold SMC migration compared with 
unstimulated controls. This migration was dose-dependently decreased by sunitinib 
and the highest concentration prevented it completely (IV). 
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4. ACUTE REJECTION 
In syngenic groups, no signs of acute rejection were observed at day 5, whereas 
monotherapy with CsA or Tac was characterized with moderate perivascular and 
diffuse interstitial inflammation (I, III, and IV). FK778 dose-dependently ameliorated 
early post-transplant inflammation in monotherapy (I). When FK778 was combined 
with CsA and Tac, it ameliorated perivascular and diffuse interstitial inflammation, 
indicating an additive effect on acute rejection (I). However, erlotinib (III) and 
sunitinib (IV) had no effects on the early inflammatory response at day 5. 
In allografts of CsA and Tac-treated rats, significantly increased numbers of CD4+ 
and CD8+ lymphocytes and ED3+ activated macrophages were seen in the renal 
interstitium compared to syngenic DA-DA grafts at day 5 (I, III and IV).  
FK778 monotherapy somewhat ameliorated the infiltration of both ED3+ activated 
macrophages and CD8+ lymphocytes, though no significant difference was found 
compared to CNI groups (I). The effect of FK778 monotherapy on CD4+ lymphocyte 
infiltration was not dose-dependent. The FK778 and CNI combination therapy 
decreased the amount of infiltrating CD8+ cells and activated macrophages at day 5, 
but the effect on CD4+ lymphocytes remained insignificant (I).  
The TKIs erlotinib and sunitinib had no effect on the early post-transplant infiltration 
of CD4+ and CD8+ lymphocytes and ED3+ activated macrophages (III and IV). 
 
5. GRAFT FUNCTION AND SERUM CREATININE LEVELS 
Because the left-sided nephrectomy was performed on postoperative day 7 and serum 
sampling frequency was once per week, the serum creatinine level was a meaningful 
indicator of graft function only after week 2. Therefore, serum creatinine levels were 
not measured in the acute rejection study groups when they were sacrificed on day 5. 
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In the syngenic group, the post-transplant serum creatinine level was approximately 
35 μmol/l (I-IV). In the CsA monotherapy group, an initial increase in the serum 
creatinine level was followed by a rather steady level of 60 μmol/l.  
FK778 combined with CsA failed to decrease the creatinine levels at most time points 
(I). With the FK778-Tac combination, there was a trend towards lower creatinine 
levels compared to Tac monotherapy, though no significant difference was found 
between these groups (I). 
TKIs had a significant effect on post-transplant graft function. Creatinine levels were 
significantly lower in imatinib-treated allografts than in CsA-monotherapy treated 
control allografts throughout the follow-up (P<0.05, II). In addition, when combined 
with CsA, erlotinib (P=0.04, III) and sunitinib (P=0.02, IV) significantly decreased 
the post-transplant serum creatinine level, maintaining better graft function.  
 
6. CHRONIC REJECTION  
No histological signs of chronic rejection were observed in syngenic grafts 90 days 
after transplantation, whereas moderate chronic changes (e.g., increased fibrosis, 
inflammation, and intimal proliferation) were observed in allografts treated with CsA 
(I-IV) or Tac monotherapy (I). The combination of FK778 and CNI significantly 
ameliorated the inflammation, fibrosis, and intimal proliferation observed in CNI 
monotherapy-treated allografts (I).  
Short-term imatinib treatment (combination therapy with CsA) significantly 
ameliorated the development of chronic rejection compared to control allografts (II), 
and only mild changes were observed. Interstitial inflammation and fibrosis, as well as 
arterial intimal proliferation and increased glomerular mesangial matrix, were 
significantly decreased in imatinib-treated allografts. In addition, the infiltration of 
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CD4+ and CD8+ T cells and activated macrophages was decreased (II).  
Erlotinib significantly ameliorated both the CADI score and individual CADI 
parameters (interstitial inflammation and mesangial matrix increase, P=0.02; fibrosis, 
P=0.03; intimal proliferation, P=0.04), CD4+ and CD8+ T-cell (P=0.04) and B-cell 
infiltration on day 90 (P=0.01, III). 
Sunitinib decreased the CADI score when combined with CsA. Sunitinib also 
significantly ameliorated chronic inflammation, fibrosis, increase in mesangial matrix, 
and intimal proliferation, as well as the infiltration of CD4+ and CD8+ lymphocytes 
and ED3+ activated macrophages (IV).  
  
7. POST-TRANSPLANT GROWTH FACTOR EXPRESSION 
 
7.1 PDGF  
In syngenic controls, PGDF expression (PDGF-A, PDGF-B, PDGFR-α, PDGFR-β) 
was almost non-existent 5 and 90 days after transplantation (I, II, and IV). In the CsA 
and Tac groups, PDGF expression was significantly increased by day 5, and this 
expression remained elevated at day 90 (I, II, and IV). PDGF ligand and receptor 
expression was noted in capillary endothelial cells and infiltrating leukocytes (I, II, 
and IV). The difference in PDGF ligand and receptor expression between CsA and 
Tac monotherapy groups remained relatively small (I). When FK778 was combined 
with CNIs, it significantly decreased the expression of PDGF ligands and receptors, 
both acute and chronic (I). 
Short-term imatinib treatment significantly inhibited the induction of PDGF-A and -B 
ligands and PDGF receptor –β (II). Expression of both PDGF-A and -B was 
decreased, especially in interstitial leukocytes and tubules (II). PDGF-B expression 
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was also significantly inhibited in arterial SMCs in imatinib-treated allografts 
compared to control allografts (II). The expression of PDGFR-β was decreased 
markedly in graft-infiltrating inflammatory cells, tubular area and in arterial SMCs 
(II). 
Sunitinib significantly decreased acute arterial expression of PDGFR-β at day 5 but 
failed to affect acute PDGF-A, PDGF-B or PDGFR-α expression (IV). However, 
sunitinib significantly decreased chronic PGDF expression (IV). 
 
7.2 TGF-β 
TGF-β expression was low in syngenic grafts at both 5 and 90 days (I). However, 
moderate TGF-β and TGF-βR expression was observed in the CsA and Tac groups at 
day 5, and this expression was mainly localized in the renal capillaries and infiltrating 
leukocytes (I). This expression remained elevated at day 90 in the CsA group, but 
only mild expression was observed in the Tac monotherapy-treated allografts (I).  
When FK778 was combined with CNIs, it significantly decreased the expression of 
TGF-β and TGF-βR, both acute and chronic, compared to CNI monotherapy (I). In 
addition, short-term imatinib treatment significantly inhibited the induction of TGF-β 





No pathological VEGF expression was observed in syngenic grafts at day 5 or 90 
(IV). However, significantly increased tubular, arterial, and inflammatory expression 
of VEGF-A was observed in CsA-treated allografts at day 5 and 90 (IV). VEGF-B 
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was expressed mainly in the arterial and tubular area and in inflammatory cells.  The 
expression pattern of VEGFR-1 and -2 was somewhat broader than that of VEGF 
ligands and also glomerular expression was observed (IV). 
Sunitinib significantly decreased acute arterial expression of VEGF-A and VEGF-B 
at day 5 (IV). In addition, prolonged VEGF ligand and receptor expression was 
prevented with sunitinib treatment (IV). 
 
7.4 EGF 
No expression of EGF or EGFR was observed in syngenic grafts at day 5 or 90 (III). 
However, the expression of EGF and EGFR was significantly increased in CsA-
treated allografts at day 5, and this expression remained elevated at day 90 (III). The 
increased EGF expression was mainly localized to inflammatory cells, whereas 
increased EGFR expression was observed in inflammatory cells and tubular cells. 
Erlotinib had no effect on acute EGF or EGFR expression (III). However, it 
significantly ameliorated chronic EGF expression (P=0.03; III). Erlotinib also 
significantly ameliorated chronic EGFR expression in inflammatory cells and tubular 












1. GROWTH FACTOR EXPRESSION IN SYNGENIC GRAFTS 
Expression of PDGF-A and -B, PDGFR-α, PDGFR-β, TGF-β, TGF-βR, EGF, EGFR, 
VEGF-A, VEGF-B, VEGFR-1, and VEGFR-2 was low in syngenic kidney grafts in 
all studies and at all time points (I-IV). This indicates that ischemia reperfusion injury 
or surgery-related factors alone are not able to induce prolonged growth factor 
expression in this animal model. This also suggests that innate immunity alone, 
without allorecognition, does not lead to allograft injury. 
 
2. FK778 AMELIORATES ACUTE AND CHRONIC REJECTION 
According to the results of article I, FK778 decreases acute rejection in a dose-
dependent manner. Because FK778 is an immunosuppressive drug, this effect is only 
logical. However, FK778 monotherapy also decreased the expression of PDGF and 
TGF-β ligands and receptors in a dose-dependent manner. Therefore, FK778 appears 
to have a beneficial effect on growth factor expression, unlike CsA (Iacopino et al. 
1997) and Tac (Khanna, Cairns, Hosenpud 1999). This effect on TGF-β and PDGF 
ligands and receptors remained when FK778 was combined with CsA or Tac. Thus, 
FK778 appears to have additive effects with CNIs with regard to the effect on the 
early post-transplant inflammatory response and favorable effects on growth factor 
expression. Therefore, FK778 could be used in combination therapy with both CsA 
and Tac for acute rejection.  
FFK778 also significantly decreased the chronic inflammation, fibrosis, and intimal 
proliferation seen in CNI monotherapy-treated allografts (I). This effect may be due, 
in part, to decreased growth factor expression. Unfortunately, clinical studies with 
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FK778 were discontinued when no results were seen for the rate of acute rejection in 
renal transplant patients after 1 year (Wlodarczyk et al. 2012). However, acute 
rejection in clinical kidney transplantation may already be treated successfully with 
current multi-therapy of CNI, corticosteroids and anti-thymocyte globulin, whereas 
chronic rejection remains the main reason for late allograft loss. According to the 
results of study I, FK778 could have had beneficial effects on chronic rejection in 
clinical transplantation if it had been launched for clinical use in transplant patients. 
  
3. SHORT-TERM IMATINIB TREATMENT PREVENTS CHRONIC REJECTION 
Imatinib inhibits the PDGF response and could be a potential intervention in clinical 
kidney transplantation (Savikko et. al. 2003). However, growth factors also have 
physiological effects, and their prolonged inhibition could cause adverse effects. Life-
long daily administration would also be very expensive.  
The results of article II show that even short-term imatinib treatment is sufficient for 
preventing the development of chronic allograft injury, and that it preserves the long-
term graft function. Early short-term treatment with imatinib also decreases chronic 
PDGF and TGF-β expression, and growth factor expression remains low even after 
imatinib has been discontinued. This indicates that the early induction of PDGF and 
TGF-β is an important mechanism in the pathophysiology of chronic rejection. 
Therefore, early short-term inhibition of the growth factor response could prevent the 
response altogether, and TKIs could be considered for induction therapies in clinical 
transplantation.  
According to these results, life-long TKI therapy may not be necessary for the 
prevention of chronic allograft injury. This makes TKIs a more convenient option for 
clinical kidney transplantation.  
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4. EGF INHIBITION WITH ERLOTINIB PREVENTS CHRONIC REJECTION 
AND MAINTAINS RENAL FUNCTION 
Erlotinib is a highly selective EGF-inhibiting TKI, and the role of EGF in the 
development of acute and chronic rejection has not been fully investigated. Chronic 
rejection is partly driven by arterial intimal proliferation, and growth factors 
participate in this process resembling of accelerated atherosclerosis. According to the 
results of paper III, inhibition of EGF by erlotinib decreases intimal proliferation after 
aortic denudation, suggesting that erlotinib may have beneficial effects on allograft 
vasculopathy. 
EGF and EGFR expression was increased during acute rejection. Inhibition of EGF 
by erlotinib had no effect on this early post-transplant expression when combined 
with CsA. However, erlotinib decreased chronic inflammation, fibrosis, the increase 
in mesangial matrix, and intimal proliferation. Therefore, inhibition of EGF by 
erlotinib prevents histological changes associated with rejection in kidney allografts. 
In addition, chronic EGF and EGFR expression decreased, and only marginal 
expression was observed, suggesting an absence of active fibrotic processes. Based on 
lower serum creatinine levels, erlotinib also maintains better allograft function than 
CsA monotherapy. This is an important finding because serum creatinine levels are an 
insensitive marker of kidney function, and a pronounced effect is needed before 
creatinine levels change.  
Erlotinib is not an immunosuppressive drug; it has no direct effect on acute rejection. 
This is important because it emphasizes that the prevention of changes associated 
with chronic rejection here (III) was not achieved by increased immunosuppression or 
decreased acute rejection, a known risk factor for chronic rejection. Erlotinib inhibits 
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the EGF response by inhibiting the EGF signaling cascade, affecting downstream 
from early EGF and EGFR expression that was monitored on day 5 by 
immunohistochemistry. Therefore, erlotinib has no effect on the amount of EGF or 
EGFR; instead, erlotinib inhibits the signaling cascade these ligands and receptors 
mediate.  
Taken together, these results indicate that EGF plays a profound role in the 
development of chronic rejection, and erlotinib could have a beneficial effect on 
chronic rejection in clinical transplantation. 
 
5. SUNITINIB PREVENTS CHRONIC ALLOGRAFT INJURY AND PRESERVES 
KIDNEY FUNCTION 
Sunitinib is a potent TKI with a wide range of activity and a more potent effect on 
PDGF inhibition than imatinib. Therefore, sunitinib could be an efficient intervention 
in chronic rejection. According to the results of article IV, sunitinib prevents 
neointimal formation after aortic denudation and decreases neointimal PDGF 
expression. This finding indicates that sunitinib has beneficial effects on post-
transplant vasculopathy. This effect may be mediated, in part, by the prevention of 
SMC proliferation and migration. Similar to erlotinib, sunitinib has no specific 
immunosuppressive mechanism and no effect on the early inflammatory response and 
acute rejection. However, as sunitinib is a potent inhibitor of both PDGF and VEGF, 
it decreased the early arterial expression of PDGFR-β, VEGF-A, VEGF-B, VEGFR-
1, and VEGFR-2. This may mediate its effect on chronic rejection. Sunitinib, like 
erlotinib and imatinib, exerts its effects by binding to the intracellular ATP-binding 
site of tyrosine kinases (Kim et al. 2006), inhibiting the function of growth factors 
instead of their early post-transplant expression. This may partly explain why 
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sunitinib had no effect on intense inflammatory PDGF and VEGF expression but 
profoundly affected later chronic rejection changes. 
Sunitinib significantly decreased the changes associated with chronic rejection when 
combined with CsA and resulted in nearly normal histology at day 90 (IV). In 
addition, chronic PDGF and VEGF expression was almost completely prevented and, 
according to serum creatinine levels, sunitinib maintained better allograft function. 
These results indicate that combined inhibition of PDGF and VEGF by sunitinib 
effectively decreases chronic allograft injury in an experimental kidney 
transplantation model. Therefore, sunitinib could have beneficial effects for the 
prevention of chronic rejection in clinical kidney transplantation. 
 
6. TYROSINE KINASE INHIBITION IN EXPERIMENTAL KIDNEY 
TRANSPLANTATION 
Growth factors are induced in various steps along the progression of disease in kidney 
transplant patients. Growth factor expression increases during the development of the 
kidney disease that originally leads to ESRD and the need for kidney transplantation, 
but may also be activated during the donor brain death and transplantation operation 
itself. In addition, growth factors are induced by innate immunity and ischemia 
reperfusion injury, which may in turn strengthen the acute rejection, a major risk 
factor for chronic rejection. 
Our studies found significant expression of PDGF, VEGF, TGF-β, and EGF during 
acute rejection in experimental kidney transplantation. Their inhibition with orally 
administered TKIs decreased the proliferation and migration of SMCs, as well as 
experimental allograft vasculopathy. Furthermore, inhibition of growth factor 
receptors decreased chronic rejection changes via a mechanism that differs from 
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cellular infiltration and appears to be additive with that of CNIs. Therefore, several 
TKIs shown here profoundly decreased chronic rejection changes, suggesting a class 
effect that could achieve beneficial results for kidney transplant patients.  
In clinical oncology tyrosine kinase inhibitors are being concidered to be used also in 
combination therapies regarding individual genetic factors and thus allowing 
personalized therapy for cancer patients (Broekman et al. 2011). The efficasy of 
growth factor inhibition or different TKIs against individual cancer depends on 
spesific mutations causing the cancer which may explain why TKIs differ in their 
effect. However, in kidney transplantation the immune response is not dependent on 
patient spesific mutations. Therefore one can speculate that TKI-treatment could be 
more standardized in clinical transplantation than in oncological field and also 
combination of different TKIs could be studied.  
Our results in article II suggest that life long growth factor inhibition may not be 
mandatory to prevent the development of chronic rejection changes. The length of a 
study periode with a one month induction therapy in experimental model is hard to 
extrapolate into clinical transplantation. However, results presented here indicate that 
the early post-transplant events and growth factor responses are important in the 
development of chronic rejection. The differences between different TKIs in the 
prevention of these changes can not be answered based on our sudies because they 
were not compared between each other. However, because of the strong correlation of 
results with these four different tyrosine kinase inhibiting drugs on the prevention of 






FK778 inhibits several growth factor RTKs and offers a different immunosuppressive 
mechanism that could supplement the effect of CNIs. Therefore, FK778 could be a 
valuable option for combination therapy with CNIs. Unfortunately, the clinical studies 
with FK778 were stopped when no significant benefit was observed in acute rejection 
after 1 year of follow-up, though the side effect profile was milder with FK778 than 
other immunosuppressive agents (Wlodarczyk et al. 2012). Our results in 
experimental model (I) indicate that FK778 could be a potent intervention for 
preventing chronic rejection. However, the effect of FK778 on chronic rejection in 
clinical kidney transplantation cannot be evaluated according to the 1-year follow-up 
results of transplantation patients. Thus, the potential effect of FK778 on chronic 
rejection remains unknown. 
Our results in article II on short-term imatinib treatment demonstrate that early PDGF 
induction plays an important role in the cellular processes leading to chronic rejection. 
If this early PDGF induction is prevented with the combination of imatinib and CsA, 
the fibrotic cascade leading to chronic allograft injury may be prevented. Thus, early 
PDGF inhibition with imatinib could be used as an induction therapy in clinical 
kidney transplantation.  
We showed in article III that EGF and EGFR expression is increased in rejecting 
renal allografts after kidney transplantation. EGF inhibitor erlotinib decreases late 
post-transplant EGF and EGFR expression when combined with CsA and prevents 
changes associated with chronic rejection. Furthermore, erlotinib maintains better 
allograft function after experimental kidney transplantation. This effect is not 
achieved by decreased acute rejection indicating that EGF is significantly involved in 
the pathogenesis of chronic allograft injury. Thus, inhibition of EGF by erlotinib 
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could improve renal allograft outcomes in kidney transplant patients. 
According to article IV, sunitinib prevents chronic rejection in an experimental rat 
kidney transplantation model when used in combination therapy with CsA. Also, 
renal graft function was preserved better with sunitinib treatment than CsA 
monotherapy. These results indicate that sunitinib could have beneficial effects in 
clinical transplantation. 
Taken together, the results in this project show that chronic rejection may be 
prevented by the inhibition of PDGF and TGF-b, PDGF and VEGF, or EGF. With a 
single TKI, it is not possible to completely rule out the existence of multiple pathways 
by other growth factors behind this effect, especially as growth factors have multiple 
interactions. However, these results indicate that growth factors play a significant role 
in mediating the rejection process, and this may be treated with TKIs, which are 
already used clinically and could offer a new intervention against allograft rejection. 
 
LIMITATIONS OF THE STUDY 
We used a standardized rat model of experimental kidney transplantation. This model 
is immunologically restricted and enables the investigation of the immunological 
rejection process. Our rats were healthy, meaning that they had no background 
disease resulting in ESRD and a need for kidney transplantation. This affects our 
results because, during the experimental transplantation, the recipients are not uremic 
and have no background disease that could affect renal function or the immunological 
response in the post-transplant period. Therefore, our model differs from clinical 
kidney transplantation, where even more pathological processes participate in renal 
injury. However, a functional kidney transplantation model with 300-g rats is 
challenging, even with healthy rats. We recognize that our animal model is not 
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perfect, but to the best of our knowledge, an experimental transplantation model with 
uremic rats does not exist. 
The number of animals we were aiming for in each group during this project was 5, 
which is a compromise between reliable results and minimal usage of laboratory 
animals. We recognize that this could be regarded as a small group size. However, 
keeping in mind the hundreds of kidney transplantations performed for this project, 
we can assure that requiring a bigger group size is much easier than providing it. 
The publications leaned heavily on immunohistochemistry, and background staining 
remains a problem when staining renal growth factors in rat. Rejecting samples may 
also be distinguishable in blind scoring due to their histological appearance, and this 
may cause bias. However, growth factors have been investigated in various acute and 
chronic kidney models and the vast literature supports our results that growth factors 
are increased during kidney disease and the rejection process. In addition, growth 
factor inhibition with TKIs significantly decreased histological rejection, indicating 
that growth factors play a profound role in the rejection process. TKIs also decreased 
serum creatinine levels, which is the most important and objective finding supporting 







Chronic allograft injury is a multifactorial process mediated by both immunological 
and non-immunological factors, leading to organ dysfunction and humoral and 
cellular rejection. Currently, no specific treatment is available for chronic allograft 
injury. Pathological growth factor expression is observed before the development of 
end-stage renal disease (ESRD), and several growth factors (e.g., PDGF, TGF-β, 
EGF, and VEGF) are induced during the rejection process. This increased growth 
factor expression is induced by multiple pathways that are unaffected or partly 
induced by modern immunosuppressive medication. Individual growth factors induce 
their own expression and, via interactions, the expression of other growth factors. 
This cascade may lead to prolonged growth factor expression and subsequent chronic 
allograft injury.  
Many growth factors exert their effects through specific receptor tyrosine kinases 
(RTKs). RTKs can be inhibited by novel tyrosine kinase inhibitors (TKIs), which are 
orally administered and clinically used to treat several malignancies. RTK inhibition 
is achieved by competitive inhibition of intracellular ATP binding. In our 
experiments, we tested the efficacy of four different drugs with RTK-inhibition 
activity on chronic rejection in a rat transplantation model.  
First, we investigated FK778, an analogue of the active metabolite of leflunomide, 
which inhibits T- and B-cell proliferation and functions by interfering in de novo 
pyrimidine biosynthesis. FK778 also inhibits PDGF-RTK both in vitro and in vivo. In 
our experiments, FK778 decreased acute rejection in a dose-dependent manner and 
had additive effects with both cyclosporine and tacrolimus, decreasing both acute and 
chronic rejection. FK778 also decreased post-transplant PDGF and TGF-β expression. 
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In our second study, we investigated short-term imatinib treatment in a chronic 
rejection model. According to our results, short-term (i.e., 30-day) treatment with 
PDGF-inhibiting TKI imatinib is sufficient to decrease subsequent chronic rejection 
changes at day 90. This short-term imatinib treatment also decreased post-transplant 
PDGF and TGF-β expression and restored allograft function. 
In the third study, we used erlotinib, a specific EGF-inhibiting TKI. We showed that, 
when combined with cyclosporine, erlotinib prevents chronic rejection changes and 
maintains better graft renal function. Erlotinib also decreased post-transplant EGF 
expression. 
In our fourth study we tested a potent, PDGF- and VEGF-inhibiting TKI, sunitinib, in 
combination with cyclosporine. Our data showed that sunitinib decreased early 
arterial expression of VEGF and PDGF as well as chronic expression of both PDGF 
and VEGF. Sunitinib decreased chronic rejection and maintained better graft function 
after transplantation. 
Taken together, our results show that growth factor inhibition via the inhibition of 
tyrosine kinases is a potent pathway to prevent chronic rejection and maintain graft 
function in the transplanted kidney. Our finding that even short-term imatinib 
treatment is sufficient to prevent chronic rejection indicates that life-long treatment 
may not be mandatory and early post-transplant events are crucial in mediating 
chronic rejection changes. TKIs imatinib, erlotinib, and sunitinib are well tolerated 
when combined with cyclosporine and prevent chronic rejection in an experimental 
kidney transplantation model. In addition, these drugs maintain better graft function 




YHTEENVETO (FINNISH SUMMARY) 
Munuaissiirto on hoitotuloksiltaan loppuvaiheen munuaisen vajaatoiminnan paras 
hoitomuoto sekä pitkäaikaisennusteen että elämänlaadun kannalta. Krooninen 
hyljintäreaktio on kuitenkin edelleen merkittävä munuaissiirtojen pitkäaikaistuloksia 
heikentävä tekijä eikä siihen tunneta toimivaa hoitoa. Kroonisen hyljinnän 
kehittymiseen vaikuttavat monet sekä immunologiset että immunologiasta 
riippumattomat tekijät ja myös potilaan edeltävä munuaissairaus voi vaikuttaa   
hyljintäreaktion voimakkuuteen.  
Monet kasvutekijät, kuten verihiutalekasvutekijä PDGF, transformoiva kasvutekijä 
TGF-beta, verisuonikasvutekijä VEGF ja epidermaalinen kasvutekijä EGF vaikuttavat 
jo loppuvaiheen munuaisen vajaatoiminnassa munuaisen fibrotisoitumiseen ja sitä 
kautta munuaisen toimminnan hiipumiseen. Lisäksi näiden kasvutekijöiden 
ilmentyminen on lisääntynyt hyljintäreaktion aikana eikä nykyisin käytössä olevalla 
immunosupressiivisella lääkityksellä pystytä estämään kasvutekijäreaktion 
aktivoitumista munuaissiirteessä.  
Monet kasvutekijät välittävät vaikutuksensa kohdesolun pinnalla olevien 
tyrosiinikinaasi-entsyymeinä toimivien reseptoreidensa kautta. Koska krooninen 
kasvutekijöiden yli-ilmentyminen on tyypillistä pahanlaatuisten kasvaimien 
yhteydessä, on näitä reseptoreita estämään kehitetty useita onkologisia lääkkeitä. 
Väitöstutkimuksen tarkoituksena oli selvittää neljän, eri tavalla tyrosiinikinaasi-
entsyymejä estävän, lääkeaineen tehoa munuaissiirteen kroonisen hyljinnän estossa 
kokeellisessa rotan munuaistensiirtomallissa. 
Ensimmäisessä osatyössä selvitettiin kokeellisen immunosupressiivisen lääkeaineen 
FK778:n tehoa yhdistettynä nykyisin käytössä oleviin kalsineuriiniestäjiin 
siklosporiiniin ja takrolimuusiin. Verihiutalekasvutekijä PDGF:n reseptoria estävä 
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FK778 esti sekä akuutin, että kroonisen hyljintäreaktion kehittymistä 
yhdistelmäterapiana kalsineuriiniestäjien kanssa ja lisäksi verihiutalekasvutekijä 
PDGF:n ja transformoiva kasvutekijä TFG-betan ilmentyminen munuaissiirteessä 
väheni. 
Toisessa osatyössä tutkittiin lyhytkestoisen imatinibihoidon tehoa kroonisen hyljinnän 
estossa yhdistettynä siklosporiiniin. Imatinibi on tyrosiinikinaasiestäjä, joka estää 
verihiutalekasvutekijän reseptoria ja siten PDGF:n vaikutusta. Tulosten perusteella 
alkuvaiheen imatinibihoito vähentää PDGF:n ja TGF-betan ilmentymistä 
munuaissiirteessä ja estää kroonisen hyljintäreaktion kehittymisen. Lisäksi 
alkuvaiheen imatinibihoito paransi siirteen munuaisfunktiota ja tämä vaikutus jatkui 
myös imatinibihoidon lopettamisen jälkeen. Näin ollen induktiotyyppinen 
alkuvaiheen kasvutekijäesto tyrosiinikinaasiestäjällä voisi estää myös myöhemmän 
hyljintäreaktion kehittymisen eikä elinikäinen lääkitys olisi välttämätöntä. 
Kolmannessa osatyössä selvitettiin epidermaalikasvutekijä EGF:n reseptoria estävän 
erlotinibin tehoa kroonisen hyljinnän estossa yhdistämällä sitä 
siklosporiinilääkitykseen. Tulosten perusteella erlotinibi estää kroonisen hyljinnän 
kehittymistä ja parantaa siirteen munuaisfunktiota pelkkään siklosporiinilääkitykseen 
verrattuna. Tulosten perusteella epidermaalikasvutekijä osallistuu kroonisen hyljinnän 
kehittymiseen munuaissiirteessä. 
Neljännessä osatyössä tutkittiin sekä verisuonikasvutekijä VEGF:ä että 
verihiutalekasvutekijä PDGF:ä estävää sunitinibia kroonisen hyljinnän estossa 
yhdessä siklosporiinin kanssa. Tulosten perusteella PDGF:n ja VEGF:n 
samanaikainen esto on tehokas hoito kroonisen hyljinnän estämisessä kokeellisessa 
munuaissiirtomallissa. Lisäksi myös sunitinibi paransi siirteen munuaisfunktiota 
pelkkään siklosporiinilääkitykseen verrattuna. 
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Tutkimustulostemme perusteella kasvutekijöiden yli-ilmentyminen on merkittävä 
kroonisen hyljinnän kehittymiseen liittyvä tekijä. Jo nyt kliinisessä käytössä olevillä 
tyrosiinikinaasiestäjillä imatinibilla, erlotinibilla ja sunitinibilla voidaan tehokkaasti 
estää kasvutekijöiden yli-ilmentyminen munuaissiirteessä ja kokeellisessa 
munuaissiirtomallissa tämä ennaltaehkäisee kroonisen hyljintäreaktion kehittymisen 
lähes täydellisesti. Lisäksi kasvutekijäilmentymisen farmakologinen estäminen 
tyrosiinikinaasiestäjillä parantaa siirteen munuaisfunktiota pelkkään 
siklosporiinilääkitykseen verrattuna. Tulostemme perusteella lyhytaikainen 
munuaissiirron jälkeinen hoito saattaisi estää myös myöhempää hyljintäreaktion 
kehittymistä eikä elinikäinen tyrosiinikinaasiestäjähoito olisi välttämätöntä. Näin 
ollen kasvutekijävaikutuksen estäminen tyrosiinikinaasiestäjillä saattaisi olla tehokas 
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